

# CITATION REPORT

List of articles citing

**Schizophrenia: a concise overview of incidence, prevalence, and mortality**

**DOI: 10.1093/epirev/mxn001**  
**Epidemiologic Reviews, 2008, 30, 67-76.**

**Source:** <https://exaly.com/paper-pdf/44312263/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1465	The burden of mental disorders. <i>Epidemiologic Reviews</i> , <b>2008</b> , 30, 1-14	4.1	302
1464	Can models of reinforcement learning help us to understand symptoms of schizophrenia?. <b>2009</b> , 249-269		
1463	Controversies surrounding the diagnosis of schizophrenia and other psychoses. <b>2009</b> , 9, 1475-86		12
1462	Who is at risk for a psychotic disorder?. <b>2009</b> , 35, 847-50		23
1461	Preclinical behavioral models for predicting antipsychotic activity. <b>2009</b> , 57, 381-418		52
1460	Packages of care for schizophrenia in low- and middle-income countries. <b>2009</b> , 6, e1000165		55
1459	Relation of schizophrenia prevalence to latitude, climate, fish consumption, infant mortality, and skin color: a role for prenatal vitamin d deficiency and infections?. <b>2009</b> , 35, 582-95		85
1458	Transcriptional interaction of an estrogen receptor splice variant and ErbB4 suggests convergence in gene susceptibility pathways in schizophrenia. <b>2009</b> , 284, 18824-32		26
1457	Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges. <b>2009</b> , 78, 1360-5		25
1456	The role of genetic variation in the causation of mental illness: an evolution-informed framework. <b>2009</b> , 14, 1072-82		172
1455	Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. <b>2009</b> , 10, 48-58		928
1454	Murray et al. (2004) revisited: is bipolar disorder identical to schizophrenia without developmental impairment?. <b>2009</b> , 120, 249-52		17
1453	The use of population based registers in psychiatric research. <b>2009</b> , 120, 386-91		53
1452	Risk factors for suicide in schizophrenia: findings from a Swedish population-based case-control study. <b>2009</b> , 108, 231-7		62
1451	11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). <b>2009</b> , 374, 620-7		906
1450	Schizophrenia. <b>2009</b> , 374, 635-45		1558
1449	Genomic and epigenomic instability, fragile sites, schizophrenia and autism. <b>2010</b> , 11, 447-69		48

1448	Depersonalization disorder. <b>2010</b> , 23, 278-83	16
1447	The role of complex emotions in inconsistent diagnoses of schizophrenia. <b>2010</b> , 198, 609-13	5
1446	Cost-effectiveness of an early intervention service for people with psychosis. <b>2010</b> , 196, 377-82	124
1445	Exploring the construct validity of the transtheoretical model to structure physical activity interventions for individuals with serious mental illness. <b>2010</b> , 34, 61-64	29
1444	Systematic reviews of categorical versus continuum models in psychosis: evidence for discontinuous subpopulations underlying a psychometric continuum. Implications for DSM-V, DSM-VI, and DSM-VII. <b>2010</b> , 6, 391-419	200
1443	Developmental vitamin D deficiency alters dopamine-mediated behaviors and dopamine transporter function in adult female rats. <b>2010</b> , 208, 159-68	89
1442	Schizophrenia and vitamin D related genes could have been subject to latitude-driven adaptation. <b>2010</b> , 10, 351	21
1441	Barriers to participation in mental health research: are there specific gender, ethnicity and age related barriers?. <b>2010</b> , 10, 103	113
1440	The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. <b>2010</b> , 10, 91	41
1439	Schizophrenia in Thailand: prevalence and burden of disease. <b>2010</b> , 8, 24	23
1438	Schizophrenia in women: implications for pregnancy and postpartum. <b>2010</b> , 14, 482-94; quiz 495	2
1437	'Programma2000': a multi-modal pilot programme on early intervention in psychosis underway in Italy since 1999. <b>2010</b> , 4, 97-103	22
1436	Reduced fertility in patients' families is consistent with the sexual selection model of schizophrenia and schizotypy. <b>2010</b> , 5, e16040	10
1435	Community beliefs about causes and risks for mental disorders: a mental health literacy survey in a rural area of Maharashtra, India. <b>2010</b> , 56, 606-22	41
1434	Endocannabinoids and Schizophrenia. <b>2010</b> , 3, 3101-3126	21
1433	Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. <b>2010</b> , 26, 943-55	71
1432	Individuals, schools, and neighborhood: a multilevel longitudinal study of variation in incidence of psychotic disorders. <b>2010</b> , 67, 914-22	102
1431	The role of genetics in the etiology of schizophrenia. <b>2010</b> , 33, 35-66	157

1430	Sex differences in schizophrenia. <b>2010</b> , 22, 417-28	441
1429	Where have all the women gone?: participant gender in epidemiological and non-epidemiological research of schizophrenia. <b>2010</b> , 119, 240-5	40
1428	Suicide in schizophrenia. <b>2010</b> , 10, 1153-64	83
1427	Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment. <b>2010</b> , 83, 140-6	40
1426	Genome-wide approaches to schizophrenia. <b>2010</b> , 83, 93-102	45
1425	Sex differences in the adolescent brain. <b>2010</b> , 72, 46-55	323
1424	Exercise therapy for schizophrenia. <b>2010</b> , CD004412	86
1423	Telephone-based nursing strategy to improve adherence to antipsychotic treatment in schizophrenia: A controlled trial. <b>2010</b> , 14, 274-81	23
1422	State anxiety, psychological stress and positive well-being responses to yoga and aerobic exercise in people with schizophrenia: a pilot study. <b>2011</b> , 33, 684-9	76
1421	HLA-DRB1 association with schizophrenia in Saudi Arabian patients. <b>2011</b> , 15, 112-7	12
1420	Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. <b>2011</b> , 7, 9-37	136
1419	Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. <b>2011</b> , 25, 567-620	294
1418	Country differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in Europe. <b>2011</b> , 26, 17-28	18
1417	Serotonin 2A receptor antagonists for treatment of schizophrenia. <b>2011</b> , 20, 1211-23	56
1416	Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. <b>2011</b> , 125, 69-76	70
1415	Increasing mortality in schizophrenia: are women at particular risk? A follow-up of 1111 patients admitted during 1980-2006 in Northern Norway. <b>2011</b> , 132, 228-32	25
1414	Advanced paternal and grandpaternal age and schizophrenia: a three-generation perspective. <b>2011</b> , 133, 120-4	56
1413	Is schizophrenia developmental adaptation to environmental menaces?. <b>2011</b> , 77, 756-62	

1412	Full length TrkB potentiates estrogen receptor alpha mediated transcription suggesting convergence of susceptibility pathways in schizophrenia. <b>2011</b> , 46, 67-78	18
1411	Increased expression of dysbindin-1A leads to a selective deficit in NMDA receptor signaling in the hippocampus. <b>2011</b> , 61, 1345-53	18
1410	Mediator and human disease. <b>2011</b> , 22, 776-87	66
1409	Effects of progressive muscle relaxation on state anxiety and subjective well-being in people with schizophrenia: a randomized controlled trial. <b>2011</b> , 25, 567-75	40
1408	Physical activity participation, functional exercise capacity and self-esteem in patients with schizophrenia. <b>2011</b> , 18, 222-229	6
1407	Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia. <b>2011</b> , 5, 471-4	12
1406	Direct medical costs associated with schizophrenia relapses in health care services in the city of Sã Paulo. <b>2011</b> , 45, 14-23	9
1405	Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. <b>2011</b> , 6, e19590	416
1404	Increased risks of acute organ dysfunction and mortality in intensive care unit patients with schizophrenia: a nationwide population-based study. <b>2011</b> , 73, 620-6	22
1403	Carbohydrate reward and psychosis: an explanation for neuroleptic induced weight gain and path to improved mental health?. <b>2011</b> , 9, 370-5	9
1402	Longitudinal Course of Schizophrenia. <b>2011</b> , 7, 205-216	1
1401	Neuregulin 3 does not confer risk for schizophrenia and smooth pursuit eye movement abnormality in a Korean population. <b>2011</b> , 10, 828-33	9
1400	Biochemical and genetic aspects of pathogenesis of schizophrenia. <b>2011</b> , 47, 407-419	2
1399	Age, sex and first treatment of schizophrenia in a population cohort. <b>2011</b> , 45, 136-41	15
1398	Violence among persons diagnosed with schizophrenia: how pharmacists can help. <b>2011</b> , 7, 421-9	2
1397	Genetics of schizophrenia: new findings and challenges. <b>2011</b> , 12, 121-44	136
1396	An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. <b>2011</b> , 261, 489-508	39
1395	Pharmacological characterization of social isolation-induced hyperactivity. <b>2011</b> , 215, 257-66	29

1394	Brain expression quantitative trait locus mapping informs genetic studies of psychiatric diseases. <b>2011</b> , 27, 123-33	23
1393	A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. <b>2011</b> , 27, 258-68	3
1392	Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. <b>2011</b> , 11, 160	14
1391	Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the 'Tolerability and quality of life' (TOOL) questionnaire. <b>2011</b> , 10, 6	7
1390	Oxidative stress in schizophrenia: an integrated approach. <b>2011</b> , 35, 878-93	304
1389	Immediate clinical assessment of medical intervention in schizophrenic patients admitted to an acute-care psychiatric unit: a retrospective, naturalistic and multicenter study. <b>2011</b> , 15, 196-203	2
1388	Sex differences in the cerebellum and frontal cortex: roles of estrogen receptor alpha and sex chromosome genes. <b>2011</b> , 93, 230-40	43
1387	Age of onset of schizophrenia: perspectives from structural neuroimaging studies. <b>2011</b> , 37, 504-13	181
1386	Molecular genetic models related to schizophrenia and psychotic illness: heuristics and challenges. <b>2011</b> , 7, 87-119	12
1385	Epidemiology of Schizophrenia. <b>2011</b> , 263-287	7
1384	Integrated treatment to achieve functional recovery for first-episode psychosis. <b>2012</b> , 2012, 962371	14
1383	Ethnicity, deprivation and psychosis: the Glasgow experience. <b>2012</b> , 21, 311-6	4
1382	Women and psychosis. <b>2012</b> , 8, 215-24	19
1381	Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia. <b>2012</b> , 92, 11-23	86
1380	Special biological issues in the management of women with schizophrenia. <b>2012</b> , 12, 823-33	8
1379	The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia. <b>2012</b> , 2012, 540273	19
1378	Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. <b>2012</b> , 2012, 916198	304
1377	Catatonic schizophrenia: a cohort prospective study. <b>2012</b> , 38, 331-7	22

1376	Mental health, poverty and development. <b>2012</b> , 11, 166-185	45
1375	Influence of patient race and ethnicity on clinical assessment in patients with affective disorders. <b>2012</b> , 69, 593-600	52
1374	Quality of medical care and excess mortality in psychiatric patients--a nationwide register-based study in Sweden. <b>2012</b> , 2, e000778	46
1373	[Antipsychotics in young adults as an indicator of the need for psychiatric care]. <b>2012</b> , 67, 271-3	
1372	Clozapine dose for schizophrenia. <b>2012</b> ,	1
1371	Neuroimaging correlates of 22q11.2 deletion syndrome: implications for schizophrenia research. <b>2012</b> , 12, 2303-13	13
1370	Heart Rate Variability in Neuropsychiatric Disorders. <b>2012</b> , 443-468	
1369	International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia. <b>2012</b> , 34, 1-12	110
1368	Genetics of schizophrenia from a clinical perspective. <b>2012</b> , 24, 393-404	9
1367	Epidemiology and comorbidity of severe mental illnesses in the community: findings from a computerized mental health registry in a large Israeli health organization. <b>2012</b> , 47, 1775-82	37
1366	Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population. <b>2012</b> , 125, 223-30	26
1365	Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls. <b>2012</b> , 76 Spec No., 43-55	65
1364	Neurocognitive function in long-term treated schizophrenia: a five-year follow-up study. <b>2012</b> , 200, 144-52	25
1363	Early childhood infections and risk of schizophrenia. <b>2012</b> , 200, 214-7	18
1362	Role of estrogen treatment in the management of schizophrenia. <b>2012</b> , 26, 549-57	34
1361	Methodology and reporting of systematic reviews and meta-analyses of observational studies in psychiatric epidemiology: systematic review. <b>2012</b> , 200, 446-53	28
1360	Differential aberrant sprouting in temporal lobe epilepsy with psychiatric co-morbidities. <b>2012</b> , 195, 144-50	22
1359	Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stress. <b>2012</b> , 26, 712-21	19

1358	Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. <b>2012</b> , 4, 19	181
1357	Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. <b>2012</b> , 2, 8	23
1356	Altered structural connectivity in neonates at genetic risk for schizophrenia: a combined study using morphological and white matter networks. <b>2012</b> , 62, 1622-33	98
1355	Real-world premorbid functioning in schizophrenia and affective disorders during the early teenage years: a population-based study of school grades and teacher ratings. <b>2012</b> , 136, 13-8	13
1354	Publication bias in meta-analyses of the efficacy of psychotherapeutic interventions for schizophrenia. <b>2012</b> , 138, 103-12	20
1353	Sex differences in sub-clinical psychosis--results from a community study over 30 years. <b>2012</b> , 139, 176-82	14
1352	Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia. <b>2012</b> , 140, 71-6	28
1351	Schizophrenia and Its Associated Sleep Disorders. <b>2012</b> , 705-713	
1350	Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. <b>2012</b> , 15, 844-61	31
1349	Prevalence of metabolic syndrome among patients with schizophrenia in Palestine. <b>2012</b> , 12, 235	29
1348	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. <b>2012</b> , 10, 92	19
1347	Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. <b>2012</b> , 7, e31660	297
1346	Obesity in pregnancy and mental health. 70-80	1
1345	Asenapine versus typical antipsychotics for schizophrenia. <b>2012</b> ,	1
1344	Childhood Mental Disorders and Risk of Schizophrenia. <b>2012</b> , 3, 43-46	
1343	Integration of Pharmacological and Psychosocial Treatment for Schizophrenia in Mexico: The Case of a Developing Country Proposal. <b>2012</b> ,	2
1342	Schizophrenia-like psychoses of epilepsy. <b>2012</b> , 5, 1-19	1
1341	Association between Ser311Cys polymorphism in the dopamine D2 receptor gene and schizophrenia risk: a meta-analysis in Asian populations. <b>2012</b> , 11, 261-70	13



1340	Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia. <b>2012</b> , 27, 403-10	
1339	Treatment prevalence and incidence of schizophrenia in Quebec using a population health services perspective: different algorithms, different estimates. <b>2012</b> , 47, 533-43	40
1338	Regulation of estrogen receptor alpha gene expression in the mouse prefrontal cortex during early postnatal development. <b>2012</b> , 13, 159-67	26
1337	A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia. <b>2012</b> , 37, 132-9	28
1336	Transcranial magnetic stimulation on the modulation of gamma oscillations in schizophrenia. <b>2012</b> , 1265, 25-35	31
1335	Gender and duration of untreated psychosis: a systematic review and meta-analysis. <b>2012</b> , 6, 115-27	50
1334	Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders. <b>2012</b> , 36, 1188-216	51
1333	Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?. <b>2012</b> , 36, 1442-62	115
1332	Does maternal body mass index during pregnancy influence risk of schizophrenia in the adult offspring?. <b>2012</b> , 13, 518-27	35
1331	Computerized neurocognitive profile in young people with 22q11.2 deletion syndrome compared to youths with schizophrenia and at-risk for psychosis. <b>2012</b> , 159B, 87-93	31
1330	No association between catechol-o-methyltransferase Val108/158Met polymorphism and schizophrenia or its clinical symptomatology in a Mexican population. <b>2013</b> , 40, 2053-8	19
1329	A schizophrenia rat model induced by early postnatal phencyclidine treatment and characterized by Magnetic Resonance Imaging. <b>2013</b> , 250, 1-8	9
1328	The effects of physical exercise in schizophrenia and affective disorders. <b>2013</b> , 263, 451-67	61
1327	Annual incidence rate of schizophrenia and schizophrenia spectrum disorders in a longitudinal population-based cohort study. <b>2013</b> , 48, 1357-65	21
1326	Socio demographic profile and utilization pattern of antipsychotic drugs among schizophrenic inpatients: a cross sectional study from western region of Nepal. <b>2013</b> , 13, 96	9
1325	Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. <b>2013</b> , 30, 286-97	49
1324	The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. <b>2013</b> , 17, 1203-20	34
1323	On schizophrenia as a "disease of humanity". <b>2013</b> , 143, 223-4	5

1322	The evolutionary paradox and the missing heritability of schizophrenia. <b>2013</b> , 162B, 122-36	60
1321	Effect of the Group Music Therapy on Brain Wave, Behavior, and Cognitive Function among Patients with Chronic Schizophrenia. <b>2013</b> , 7, 168-74	17
1320	Genetics of childhood-onset schizophrenia. <b>2013</b> , 22, 675-87	17
1319	Circular inferences in schizophrenia. <b>2013</b> , 136, 3227-41	114
1318	Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. <b>2013</b> , 151, 43-7	148
1317	Postmortem analysis of cardiovascular deaths in schizophrenia: a 10-year review. <b>2013</b> , 150, 398-403	29
1316	Epidemiological and clinical characterization following a first psychotic episode in major depressive disorder: comparisons with schizophrenia and bipolar I disorder in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS). <b>2013</b> , 39, 756-65	38
1315	Sex-specific association of the ST8SIA11 gene with schizophrenia in a Spanish population. <b>2013</b> , 210, 1293-5	19
1314	Transcriptome study of differential expression in schizophrenia. <b>2013</b> , 22, 5001-14	67
1313	Two gene co-expression modules differentiate psychotics and controls. <b>2013</b> , 18, 1308-14	107
1312	Serum testosterone levels are related to cognitive function in men with schizophrenia. <b>2013</b> , 38, 1717-28	62
1311	Psychosis in children and youth: focus on early-onset schizophrenia. <b>2013</b> , 34, 296-305; quiz 305-6	8
1310	Exercise therapy improves mental and physical health in schizophrenia: a randomised controlled trial. <b>2013</b> , 127, 464-73	147
1309	Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China. <b>2013</b> , 38, 1424-30	39
1308	Progressive muscle relaxation in persons with schizophrenia: a systematic review of randomized controlled trials. <b>2013</b> , 27, 291-8	36
1307	A systematic review and meta-analysis of recovery in schizophrenia. <b>2013</b> , 39, 1296-306	462
1306	The genetic overlap between schizophrenia and height. <b>2013</b> , 151, 226-8	8
1305	[Effectiveness of a joint project between primary care and mental health to improve the recording of cardiovascular risk factors in patients with psychosis]. <b>2013</b> , 45, 307-14	6

1304	Lifetime and 12-month prevalence rates of sub-clinical psychosis symptoms in a community cohort of 50-year-old individuals. <b>2013</b> , 28, 302-7	10
1303	C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. <b>2013</b> , 28, 161-7	22
1302	A population-based cohort study to elucidate temporal relationship between schizophrenia and metabolic syndrome (KCIS no. PSY3). <b>2013</b> , 151, 158-64	6
1301	Additive genetic variation in schizophrenia risk is shared by populations of African and European descent. <b>2013</b> , 93, 463-70	55
1300	Lipid effects of psychiatric medications. <b>2013</b> , 15, 292	2
1299	Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population. <b>2013</b> , 162B, 538-45	20
1298	Morphology and microstructure of subcortical structures at birth: a large-scale Asian neonatal neuroimaging study. <b>2013</b> , 65, 315-23	24
1297	The nicotinic $\alpha$ 7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys. <b>2013</b> , 64, 191-6	27
1296	Alterations in the cerebral white matter of genetic high risk offspring of patients with schizophrenia spectrum disorder. <b>2013</b> , 40, 187-92	7
1295	Integrating fMRI and SNP data for biomarker identification for schizophrenia with a sparse representation based variable selection method. <b>2013</b> , 6 Suppl 3, S2	19
1294	There is a need for physiotherapists in the multidisciplinary treatment of schizophrenia. <b>2013</b> , 35, 239-242	1
1293	The Effect of an Alternative Term for Schizophrenia in Reducing Discriminatory Attitudes of the English-Speaking Lay Public. <b>2013</b> , 42, 3-33	2
1292	[Schizophrenia--a mild encephalitis?]. <b>2013</b> , 81, 250-9	8
1291	Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden. <b>2013</b> , 39, 527-36	66
1290	Cardiovascular disease risk in schizophrenia patients: a case control study. <b>2013</b> , 7, 2694-6	8
1289	Genome-wide association study of schizophrenia using microsatellite markers in the Japanese population. <b>2013</b> , 23, 117-23	5
1288	Psychosis Following Traumatic Brain Injury. <b>2013</b> , 14, 21-41	22
1287	Catechol-modified Chitosan System as a Bio-amplifier for Schizophrenia Treatment Analysis. <b>2013</b> , 1572, 1	1

1286	Antipsychotics: Neurobiological Bases for a Therapeutic Approach. <b>2013</b> , 23, 91-98	2
1285	A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. <b>2013</b> , 12, 240-50	168
1284	Sex differences in the genetic risk for schizophrenia: history of the evidence for sex-specific and sex-dependent effects. <b>2013</b> , 162B, 698-710	59
1283	Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. <b>2013</b> ,	2
1282	First-rank symptoms for schizophrenia. <b>2013</b> ,	0
1281	Yoga for schizophrenia. <b>2013</b> ,	2
1280	Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. <b>2013</b> ,	12
1279	Aripiprazole for neuroleptic induced hyperprolactinaemia. <b>2013</b> ,	1
1278	Study on psychoeducation enhancing results of adherence in patients with schizophrenia (SPERA-S): study protocol for a randomized controlled trial. <b>2013</b> , 14, 323	6
1277	Cognitive behaviour therapy (brief versus standard duration) for schizophrenia. <b>2013</b> ,	
1276	Schizophrenia and OCD: comparative characteristics. 1-21	1
1275	Male-biased autosomal effect of 16p13.11 copy number variation in neurodevelopmental disorders. <b>2013</b> , 8, e61365	88
1274	Distinct molecular phenotypes in male and female schizophrenia patients. <b>2013</b> , 8, e78729	41
1273	Base rates, blindness, and schizophrenia. <b>2013</b> , 4, 157	14
1272	Accounting for individual differences in human associative learning. <b>2013</b> , 4, 588	7
1271	Testosterone induces molecular changes in dopamine signaling pathway molecules in the adolescent male rat nigrostriatal pathway. <b>2014</b> , 9, e91151	61
1270	The impact of environmental factors in severe psychiatric disorders. <b>2014</b> , 8, 19	174
1269	Association of dopamine D1 receptor gene polymorphism with schizophrenia: a meta-analysis. <b>2014</b> , 10, 1133-9	10

1268	Haloperidol discontinuation for schizophrenia. <b>2014,</b>	1
1267	Understanding tDCS effects in schizophrenia: a systematic review of clinical data and an integrated computation modeling analysis. <b>2014,</b> 11, 383-94	53
1266	Insight development in schizophrenia: the construction of dangerousness in relapse. <b>2014,</b> 24, 591-602	3
1265	Modelling the incidence and mortality of psychotic disorders: data from the second Australian national survey of psychosis. <b>2014,</b> 48, 352-9	18
1264	Psychiatry. <b>2014,</b> 1061-1072.e2	
1263	Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. <b>2014,</b> 17, 91-104	35
1262	[Clinical Practice Guidelines for Management of Schizophrenia: Evaluation Using AGREE II]. <b>2014,</b> 44 Suppl 1, 3-12	0
1261	Diminished emotion expressivity but not experience in men and women with schizophrenia. <b>2014,</b> 123, 796-801	18
1260	Development and Reliability Testing of a Health Action Process Approach Inventory for Physical Activity Participation among Individuals with Schizophrenia. <b>2014,</b> 5, 68	18
1259	Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. <b>2014,</b> 5, 137	184
1258	Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. <b>2014,</b> CD010646	11
1257	Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first-episode psychosis. <b>2014,</b>	1
1256	Psychometric evaluation of a new instrument in Spanish to measure self-care requisites in patients with schizophrenia. <b>2014,</b> 50, 93-101	2
1255	The prevalence of schizophrenia in mainland China: evidence from epidemiological surveys. <b>2014,</b> 130, 244-56	84
1254	Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. <b>2014,</b> 29, 183-9	31
1253	Gendered mental disorders: masculine and feminine stereotypes about mental disorders and their relation to stigma. <b>2014,</b> 154, 546-65	29
1252	Which pathways to psychiatric care lead to earlier treatment and a shorter duration of first-episode psychosis?. <b>2014,</b> 14, 72	40
1251	Application of proteomics in diagnosis of ADHD, schizophrenia, major depression, and suicidal behavior. <b>2014,</b> 95, 283-315	3

1250	Developmentally vitamin D-deficient rats show enhanced prepulse inhibition after acute $\Delta^9$ -tetrahydrocannabinol. <b>2014</b> , 25, 236-44	10
1249	A systematic review of the aerobic exercise program variables for people with schizophrenia. <b>2014</b> , 13, 260-6	30
1248	The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. <b>2014</b> , 29, 63-76	195
1247	Genetic Variants of Interleukin-10 Gene Promoter are Associated with Schizophrenia in Saudi Patients: A Case-Control Study. <b>2014</b> , 6, 558-65	6
1246	The onset and offset of psychosis--and what happens in between--a commentary on Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 Study by Morgan et al. (2014). <b>2014</b> , 44, 2705-11	2
1245	Animal Models for Brain Research. <b>2014</b> , 3-46	
1244	The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis. <b>2014</b> , 29, 77-85	7
1243	Sex and schizophrenia: a review of gender differences. <b>2014</b> , 6, 61-69	48
1242	Trend in rates for deaths with mention of schizophrenia on death certificates of US residents, 1999-2010. <b>2014</b> , 49, 1083-91	3
1241	Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. <b>2014</b> , 15, 133-42	9
1240	Money matters: does the reimbursement policy for second generation antipsychotics influence the number of recorded schizophrenia patients and the burden of stigmatization?. <b>2014</b> , 49, 531-9	1
1239	Cannabidiol as a potential treatment for psychosis. <b>2014</b> , 24, 51-64	62
1238	Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia - an individual patient data meta-analysis. <b>2014</b> , 24, 1067-77	7
1237	Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or $\Delta^9$ -tetrahydrocannabinol (THC). <b>2014</b> , 52, 53-69	45
1236	Schizophrenia. <b>2014</b> ,	5
1235	Pragmatic Disorders. <b>2014</b> ,	46
1234	Reviewing the ketamine model for schizophrenia. <b>2014</b> , 28, 287-302	185
1233	Use of very-high-dose olanzapine in treatment-resistant schizophrenia. <b>2014</b> , 159, 411-4	12

1232	Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. <b>2014</b> , 16, 277-88	62
1231	Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. <b>2014</b> , 159, 404-10	26
1230	The adenosine neuromodulation system in schizophrenia. <b>2014</b> , 119, 395-449	27
1229	First-contact incidence of psychosis in north-eastern Italy: influence of age, gender, immigration and socioeconomic deprivation. <b>2014</b> , 205, 127-34	40
1228	Epidemiology of Psychiatric Disorders. <b>2014</b> , 2389-2427	1
1227	The discovery and development of new potential antioxidant agents for the treatment of neurodegenerative diseases. <b>2014</b> , 9, 1205-22	35
1226	New molecule in the etiology of schizophrenia: urotensin II. <b>2014</b> , 68, 133-6	2
1225	Illness management and recovery programme for people with severe mental illness. <b>2014</b> ,	2
1224	P-glycoprotein activity in the blood-brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment. <b>2014</b> , 85, 548-53	7
1223	[Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy]. <b>2014</b> , 85, 363-75; quiz 376-7	7
1222	Clinical pain in schizophrenia: a systematic review. <b>2014</b> , 15, 457-67	59
1221	Excess early mortality in schizophrenia. <b>2014</b> , 10, 425-48	393
1220	Mitochondrial DNA (mtDNA) variants in the European haplogroups HV, JT, and U do not have a major role in schizophrenia. <b>2014</b> , 165B, 607-17	8
1219	Sex differences in first-episode psychosis and in people at ultra-high risk. <b>2014</b> , 215, 314-22	19
1218	Genetics of Schizophrenia. <b>2014</b> , 59-70	1
1217	Prevalence of schizophrenia disability and associated mortality among Chinese men and women. <b>2014</b> , 220, 181-7	23
1216	Reliability and validity of the Arizona sexual experiences scale-Arabic version in Tunisian patients with schizophrenia. <b>2014</b> , 55, 1473-7	13
1215	Effects of MK-801 treatment across several pre-clinical analyses including a novel assessment of brain metabolic function utilizing PET and CT fused imaging in live rats. <b>2014</b> , 77, 325-33	9

1214	Aripiprazole (ABILIFY MAINTENANCE): a review of its use as maintenance treatment for adult patients with schizophrenia. <b>2014</b> , 74, 1097-110	27
1213	Gender influence on schizophrenia-relevant abnormalities in a cuprizone demyelination model. <b>2014</b> , 62, 1629-44	13
1212	Anhedonia: A Comprehensive Handbook Volume II. <b>2014</b> ,	1
1211	Antipsychotics, chlorpromazine and haloperidol inhibit voltage-gated proton currents in BV2 microglial cells. <b>2014</b> , 738, 256-62	16
1210	The economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matching. <b>2014</b> , 29, 479-89	36
1209	What visual illusions teach us about schizophrenia. <b>2014</b> , 8, 63	97
1208	Operational Criteria Checklist for Psychotic Illness and Affective Illness (OPCRIT+) for diagnosing schizophrenia in people with psychotic symptoms. <b>2014</b> ,	4
1207	Can the new epidemiology of schizophrenia help elucidate its causation?. <b>2014</b> , 31, 1-5	8
1206	Investigating the potential genetic association between RANBP9 polymorphisms and the risk of schizophrenia. <b>2015</b> , 11, 2975-80	7
1205	Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients. <b>2015</b> , 21, 868-79	20
1204	Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis. <b>2015</b> , CD011021	13
1203	Schizophrenia. <b>2015</b> , 1, 15067	432
1202	Disrupted-in-schizophrenia-1 (DISC1) Regulates Endoplasmic Reticulum Calcium Dynamics. <b>2015</b> , 5, 8694	24
1201	The Theory of Neural Cognition Applied to Robotics. <b>2015</b> , 12, 74	7
1200	Faculty perceptions of accommodations, strategies, and psychiatric advance directives for university students with mental illnesses. <b>2015</b> , 38, 342-8	10
1199	Schizophrenia and Other Psychoses. <b>2015</b> , 791-856	2
1198	Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study. <b>2015</b> , 5, 10793	23
1197	Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. <b>2015</b> ,	



1196	'As required' medication regimens for seriously mentally ill people in hospital. <b>2015</b> , CD003441	20
1195	Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. <b>2015</b> , 3,	9
1194	Acceptance and Commitment Therapy for schizophrenia and related disorders. <b>2015</b> ,	1
1193	Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK. <b>2015</b> , 5, e009010	58
1192	Neural substrate of quality of life in patients with schizophrenia: a magnetisation transfer imaging study. <b>2015</b> , 5, 17650	15
1191	Self-help and guided self-help interventions for schizophrenia and related disorders. <b>2015</b> ,	3
1190	Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study. <b>2015</b> , 69, 497-503	5
1189	FitForLife: study protocol for a randomized controlled trial. <b>2015</b> , 16, 553	1
1188	Yoga versus standard care for schizophrenia. <b>2015</b> , CD010554	20
1187	Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. <b>2015</b> , CD010646	6
1186	Detection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools. <b>2015</b> , 13, 432-440	2
1185	Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. <b>2015</b> , 4, 270-8	12
1184	Asenapine versus placebo for schizophrenia. <b>2015</b> , CD011458	6
1183	Electroconvulsive therapy for treatment-resistant schizophrenia. <b>2015</b> ,	0
1182	Perceptions of family criticism and warmth and their link to symptom expression in racially/ethnically diverse adolescents and young adults at clinical high risk for psychosis. <b>2015</b> , 9, 476-86	9
1181	Scoping review of research in Australia on the co-occurrence of physical and serious mental illness and integrated care. <b>2015</b> , 24, 421-38	14
1180	Factors of caregiver burden and family functioning among Taiwanese family caregivers living with schizophrenia. <b>2015</b> , 24, 1546-56	48
1179	Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012. <b>2015</b> , 22, 435-55	48

1178 . 2015,

1177	Association of metabotropic glutamate receptor 3 gene polymorphisms with schizophrenia risk: evidence from a meta-analysis. <b>2015</b> , 11, 823-33	6
1176	Transcranial direct current stimulation (possible therapeutic applications in psychiatric disorders in adults and children. <b>2015</b> , 4, 341-346	0
1175	Apolipoprotein E polymorphism is associated with susceptibility to schizophrenia among Saudis. <b>2015</b> , 11, 869-76	14
1174	Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. <b>2015</b> , 16, 24475-89	18
1173	Changes in Astroglial Markers in a Maternal Immune Activation Model of Schizophrenia in Wistar Rats are Dependent on Sex. <b>2015</b> , 9, 489	27
1172	Modulating pathological oscillations by rhythmic non-invasive brain stimulation-a therapeutic concept?. <b>2015</b> , 9, 33	14
1171	Conceptualization and treatment of negative symptoms in schizophrenia. <b>2015</b> , 5, 352-61	48
1170	Structured Walking and Chronic Institutionalized Schizophrenia Inmates: A pilot RCT Study on Quality of Life. <b>2015</b> , 8, 238-48	17
1169	Transcranial direct current stimulation in psychiatric disorders. <b>2015</b> , 5, 88-102	106
1168	Comparative Study on Serum Levels of 10 Trace Elements in Schizophrenia. <b>2015</b> , 10, e0133622	23
1167	Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects. <b>2015</b> , 6, 139	50
1166	Editorial: Cognition Across the Psychiatric Disorder Spectrum: From Mental Health to Clinical Diagnosis. <b>2015</b> , 6, 110	3
1165	Gender differences in individuals at high-risk of psychosis: a comprehensive literature review. <b>2015</b> , 2015, 430735	60
1164	A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. <b>2015</b> , 2015, 615356	95
1163	The Protective Effects of Areca catechu Extract on Cognition and Social Interaction Deficits in a Cuprizone-Induced Demyelination Model. <b>2015</b> , 2015, 426092	13
1162	Asenapine versus placebo for schizophrenia. <b>2015</b> ,	
1161	Mirtazapine (adjunct) versus placebo for schizophrenia. <b>2015</b> ,	1

1160	Schizophrenia and psychosis. <b>2015</b> , 774-792	4
1159	A co-expression network analysis reveals lncRNA abnormalities in peripheral blood in early-onset schizophrenia. <b>2015</b> , 63, 1-5	35
1158	Biological factors underlying sex differences in neurological disorders. <b>2015</b> , 65, 139-50	80
1157	Efficacy and safety of extract of Ginkgo biloba as an adjunct therapy in chronic schizophrenia: A systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. <b>2015</b> , 228, 121-7	26
1156	Probing the Dynamic Updating of Value in Schizophrenia Using a Sensory-Specific Satiety Paradigm. <b>2015</b> , 41, 1115-22	11
1155	«Treatment Resistance» Enigma Resolved by Pharmacogenomics - A Case Study of Clozapine Therapy in Schizophrenia. <b>2015</b> , 34, 223-227	7
1154	An evaluation of variation in published estimates of schizophrenia prevalence from 1990-2013: a systematic literature review. <b>2015</b> , 15, 193	147
1153	No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia. <b>2015</b> , 230, 200-4	6
1152	Relationship of serum testosterone levels with cognitive function in chronic antipsychotic-treated male patients with schizophrenia. <b>2015</b> , 7, 323-9	6
1151	A systematic review of the antipsychotic properties of cannabidiol in humans. <b>2015</b> , 162, 153-61	158
1150	First rank symptoms for schizophrenia. <b>2015</b> , 1, CD010653	19
1149	Mitochondrial dysfunction in schizophrenia: an evolutionary perspective. <b>2015</b> , 134, 13-21	19
1148	DNA methylation in schizophrenia: progress and challenges. <b>2015</b> , 60, 149-155	5
1147	Graph analysis of dream reports is especially informative about psychosis. <b>2014</b> , 4, 3691	52
1146	Course and outcome of schizophrenia in asian countries: review of research in the past three decades. <b>2015</b> , 14, 3-12	13
1145	Prevalence of psychosis in black ethnic minorities in Britain: analysis based on three national surveys. <b>2015</b> , 50, 1057-64	26
1144	The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. <b>2015</b> , 16, 25	32
1143	Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. <b>2015</b> , 40, 1742-51	134

1142	Analyses of Heart Rate, Respiration and Cardiorespiratory Coupling in Patients with Schizophrenia. <b>2015</b> , 17, 483-501	25
1141	Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. <b>2015</b> , 69, 102-9	19
1140	Schizophrenia and violence: realities and recommendations. <b>2015</b> , 1, 21-42	30
1139	Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D. <b>2015</b> , 72, 179-88	15
1138	[Neuroleptic malignant syndrome : Rare cause of fever of unknown origin]. <b>2015</b> , 64, 527-31	1
1137	Cumulative stress pathophysiology in schizophrenia as indexed by allostatic load. <b>2015</b> , 60, 120-9	38
1136	Incidence of psychotic disorders among first-generation immigrants and refugees in Ontario. <b>2015</b> , 187, E279-E286	80
1135	Sleep in Schizophrenia: Pathology and Treatment. <b>2015</b> , 10, 49-55	36
1134	Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East. <b>2015</b> , 11, 915-24	4
1133	Isolation rearing impaired sensorimotor gating but increased pro-inflammatory cytokines and disrupted metabolic parameters in both sexes of rats. <b>2015</b> , 55, 173-83	33
1132	Angiogenesis in the pathophysiology of schizophrenia - a comprehensive review and a conceptual hypothesis. <b>2015</b> , 128, 79-93	19
1131	Subclinical psychosis syndromes in the general population: results from a large-scale epidemiological survey among residents of the canton of Zurich, Switzerland. <b>2015</b> , 24, 69-77	24
1130	A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. <b>2015</b> , 164, 127-35	184
1129	Childhood trauma mediates the association between ethnic minority status and more severe hallucinations in psychotic disorder. <b>2015</b> , 45, 133-42	14
1128	Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia. <b>2015</b> , 165, 157-62	31
1127	Expression quantitative trait loci (eQTLs) in microRNA genes are enriched for schizophrenia and bipolar disorder association signals. <b>2015</b> , 45, 2557-69	9
1126	Increased SNARE Protein-Protein Interactions in Orbitofrontal and Anterior Cingulate Cortices in Schizophrenia. <b>2015</b> , 78, 361-73	40
1125	Genetics and genomics of psychiatric disease. <b>2015</b> , 349, 1489-94	249

1124	Semaphorin and plexin gene expression is altered in the prefrontal cortex of schizophrenia patients with and without auditory hallucinations. <b>2015</b> , 229, 850-7	21
1123	Adolescent testosterone influences BDNF and TrkB mRNA and neurotrophin-interneuron marker relationships in mammalian frontal cortex. <b>2015</b> , 168, 661-70	9
1122	Prevalence of psychotic disorders in an urban area of France. <b>2015</b> , 15, 204	10
1121	Supplementation of antipsychotic treatment with sarcosine (GlyT1 inhibitor) causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. <b>2015</b> , 606, 7-12	22
1120	Social cognition in schizophrenia. <b>2015</b> , 16, 620-31	521
1119	Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. <b>2015</b> , 11, 1709-31	26
1118	Contribution of sex hormones to gender differences in schizophrenia: A review. <b>2015</b> , 18, 2-14	43
1117	Three dysconnectivity patterns in treatment-resistant schizophrenia patients and their unaffected siblings. <b>2015</b> , 8, 95-103	15
1116	[Psychoeducation in schizophrenia]. <b>2015</b> , 44, 143-9	3
1115	Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia. <b>2015</b> , 41, 637-43	15
1114	Diabetes mellitus and severe mental illness: mechanisms and clinical implications. <b>2015</b> , 11, 79-89	83
1113	Psychopathology in Women. <b>2015</b> ,	1
1112	Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia. <b>2015</b> , 41, 764-71	12
1111	MK-801-induced behavioural sensitisation alters dopamine release and turnover in rat prefrontal cortex. <b>2015</b> , 232, 509-17	5
1110	Application of Transcranial Direct Current Stimulation in Psychiatry. <b>2016</b> , 55, 158	4
1109	The Benefits of Antipsychotic Drugs: Symptom Control and Improved Quality of Life. <b>2016</b> , 295-309	4
1108	Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia. <b>2016</b> , 11, e0148539	16
1107	Association between miR-137 polymorphism and risk of schizophrenia: a meta-analysis. <b>2016</b> , 15,	6

1106	Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. <b>2016</b> , 7, 130	37
1105	Psychosis and the Control of Lucid Dreaming. <b>2016</b> , 7, 294	26
1104	Psychotic disorders in women. 269-293	
1103	Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia: A 12-Month Observational Prospective Cohort Study. <b>2016</b> , 36, 206-12	6
1102	Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia. <b>2016</b> , 31, 325-31	14
1101	Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia. <b>2016</b> , 77, 53-72	25
1100	A Case Study on Promoting Neuroplasticity in a Patient With Schizophrenia. <b>2016</b> , 52, 95-101	
1099	The -141C Ins/Del and Taq1A polymorphism in the dopamine D2 receptor gene may confer susceptibility to schizophrenia in Asian populations. <b>2016</b> , 30, 1-7	8
1098	Examining gender difference in adult-onset psychosis in Hong Kong. <b>2016</b> , 10, 324-33	11
1097	Exploring the presence of narcolepsy in patients with schizophrenia. <b>2016</b> , 16, 177	17
1096	Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia. <b>2016</b> , 32, 1671-1679	9
1095	Polymorphisms of the TCF4 gene are associated with the risk of schizophrenia in the Han Chinese. <b>2016</b> , 171, 1006-1012	7
1094	Deep brain stimulation. <b>2016</b> , 309-324	
1093	Risk assessment for aggressive behaviour in schizophrenia. <b>2016</b> ,	3
1092	Meta-Ethnography of Qualitative Research on the Experience of Being a Partner to an Individual with Schizophrenia Spectrum Disorder. <b>2017</b> , 38, 219-232	1
1091	Increased prevalence of self-reported psychotic illness predicted by crystal methamphetamine use: Evidence from a high-risk population. <b>2016</b> , 38, 16-20	23
1090	Yoga as part of a package of care versus standard care for schizophrenia. <b>2016</b> ,	3
1089	Oestrogen (adjunct) versus placebo for women with schizophrenia. <b>2016</b> ,	

1088	Gender differences in CNV burden do not confound schizophrenia CNV associations. <b>2016</b> , 6, 25986	6
1087	Psychiatric Disorders and Diabetes. <b>2016</b> , 840-858	2
1086	Targeting the Endocannabinoid System in Psychiatric Illness. <b>2016</b> , 36, 691-703	21
1085	Effect on the expression of and after neonatal lesion in the lymphocytes, nucleus accumbens, hippocampus and prefrontal cortex: comparative analysis between juvenile and adult Wistar rats. <b>2016</b> , 153, 13	3
1084	Early interventions in risk groups for schizophrenia: what are we waiting for?. <b>2016</b> , 2, 16003	80
1083	Physical Health Decision-Making Autonomy Preferences for Adults with Severe Mental Illness in Integrated Care. <b>2016</b> , 42, 281-294	9
1082	Visual mismatch negativity (vMMN): A review and meta-analysis of studies in psychiatric and neurological disorders. <b>2016</b> , 80, 76-112	76
1081	Could cannabidiol be used as an alternative to antipsychotics?. <b>2016</b> , 80, 14-21	21
1080	Three-month paliperidone palmitate - a new treatment option for schizophrenia. <b>2016</b> , 9, 899-904	7
1079	Yoga versus non-standard care for schizophrenia. <b>2016</b> ,	4
1078	The Neurobiological Basis for Social Affiliation in Autism Spectrum Disorder and Schizophrenia. <b>2016</b> , 3, 154-164	
1077	Central- and autonomic nervous system coupling in schizophrenia. <b>2016</b> , 374,	28
1076	Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records. <b>2016</b> , 70, 450-5	17
1075	Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study. <b>2016</b> , 174, 137-143	12
1074	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. <b>2016</b> , 50, 410-72	409
1073	Effects of the inducible nitric oxide synthase inhibitor aminoguanidine in two different rat models of schizophrenia. <b>2016</b> , 309, 14-21	11
1072	Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review. <b>2016</b> , 26, 410-27	69
1071	Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway. <b>2016</b> , 36, 5160-9	84

1070	Lack of Gender-Related Differences in Childhood-Onset Schizophrenia. <b>2016</b> , 55, 792-9	14
1069	Evidence of sexual dimorphism in D1 and D2 dopaminergic receptors expression in frontal cortex and striatum of young rats. <b>2016</b> , 100, 62-66	12
1068	Brain development in adolescents at ultra-high risk for psychosis: Longitudinal changes related to resilience. <b>2016</b> , 12, 542-549	27
1067	Gene expression elucidates functional impact of polygenic risk for schizophrenia. <b>2016</b> , 19, 1442-1453	622
1066	Effect of Community-Based Social Skills Training and Tai-Chi Exercise on Outcomes in Patients with Chronic Schizophrenia: A Randomized, One-Year Study. <b>2016</b> , 49, 345-355	14
1065	Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. <b>2016</b> , 19, 1433-1441	291
1064	The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. <b>2016</b> , 3, 1049-1058	110
1063	Pharmacological treatment of schizophrenia – review of progress. <b>2016</b> , 20, 28-35	7
1062	Long-acting aripiprazole (depot) versus placebo for schizophrenia. <b>2016</b> ,	78
1061	Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. <b>2016</b> , 10, 365-77	53
1060	Social Preference and Glutamatergic Dysfunction: Underappreciated Prerequisites for Social Dysfunction in Schizophrenia. <b>2016</b> , 39, 587-596	18
1059	Pronounced prefronto-temporal cortical thinning in schizophrenia: Neuroanatomical correlate of suicidal behavior?. <b>2016</b> , 176, 151-157	40
1058	Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study. <b>2017</b> , 20, 11-21	39
1057	Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. <b>2016</b> , 7, CD010832	3
1056	The Gut-Brain Axis, BDNF, NMDA and CNS Disorders. <b>2016</b> , 41, 2819-2835	114
1055	Potential drug-drug interaction in Mexican patients with schizophrenia. <b>2016</b> , 20, 249-53	4
1054	[Why and how to treat psychosis earlier?]. <b>2016</b> , 45, 992-1000	2
1053	Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. <b>2016</b> ,	1



1052	Validity and Reliability of the Arabic Version of the Positive and Negative Syndrome Scale. <b>2016</b> , 49, 181-7	12
1051	Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. <b>2016</b> , 31, 84-92	15
1050	Two-stage replication of previous genome-wide association studies of AS3MT-CNNM2-NT5C2 gene cluster region in a large schizophrenia case-control sample from Han Chinese population. <b>2016</b> , 176, 125-130	41
1049	Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject. <b>2016</b> , 6, 335-342	7
1048	Stratifying empiric risk of schizophrenia among first degree relatives using multiple predictors in two independent Indian samples. <b>2016</b> , 24, 79-84	4
1047	The Glutamate mGluR5 Receptor as a Pharmacological Target to Enhance Cognitive Function: Emerging Evidence from Psychosis Models. <b>2016</b> , 731-750	
1046	Wendan decoction (Traditional Chinese medicine) for schizophrenia. <b>2016</b> ,	3
1045	Open Dialogue for psychosis or severe mental illness. <b>2016</b> ,	1
1044	Mortality Rates in Users of Typical and Atypical Antipsychotics: A Database Study in Poland. <b>2016</b> , 3, 345-351	6
1043	Extraordinary system of delusions and the social functioning - a case study. <b>2016</b> , 17, 19-23	
1042	Women and schizophrenia. 294-306	
1041	Neurodevelopmental Theories of Schizophrenia: Twenty-First Century Perspectives. <b>2016</b> , 1-46	
1040	Experiences of medication adherence among people with schizophrenia: a systematic review protocol of qualitative evidence. <b>2016</b> , 14, 51-7	
1039	Improving the Physical Health Monitoring of City & Hackney Assertive Outreach Service Patients. <b>2016</b> , 5,	
1038	Lurasidone versus typical antipsychotics for schizophrenia. <b>2016</b> ,	
1037	Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. <b>2016</b> , 4, CD010631	16
1036	Genome-wide association study with the risk of schizophrenia in a Korean population. <b>2016</b> , 171B, 257-65	2
1035	Employment and income among first-time cases diagnosed with non-affective psychosis in Stockholm, Sweden: a follow-up study 2004/2005-2010. <b>2016</b> , 51, 259-67	5

1034	Association between actigraphy-derived physical activity and cognitive performance in patients with schizophrenia. <b>2016</b> , 46, 2375-84	18
1033	Caffeine and Stress Promote a More Liberal Bias on Tasks Assessing Hallucination-Like Experiences and False Memory in a Nonclinical Sample. <b>2016</b> , 6, 126-133	1
1032	Exploring Differences between Successful and Unsuccessful Mental Disorder Defences. <b>2016</b> , 58, 161-193	1
1031	Can Oxytocin Enhance Social Affiliation in Schizophrenia?. <b>2016</b> , 3, 131-143	
1030	Relationship between ST8SIA2, polysialic acid and its binding molecules, and psychiatric disorders. <b>2016</b> , 1860, 1739-52	30
1029	Effects of sex and DTNBP1 (dysbindin) null gene mutation on the developmental GluN2B-GluN2A switch in the mouse cortex and hippocampus. <b>2016</b> , 8, 14	11
1028	Access and latency to first antipsychotic treatment in Italian patients with schizophrenia and other schizophrenic spectrum disorders across different epochs. <b>2016</b> , 31, 113-20	4
1027	Risperidone (depot) for schizophrenia. <b>2016</b> , 4, CD004161	12
1026	Prevalence of schizophrenia and related disorders in Malaga (Spain): results using multiple clinical databases. <b>2016</b> , 25, 38-48	16
1025	Schizophrenia. <b>2016</b> , 388, 86-97	836
1024	Evidence of Common Genetic Overlap Between Schizophrenia and Cognition. <b>2016</b> , 42, 832-42	69
1023	Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain. <b>2016</b> , 36, 479-90	2
1022	Early Life Bereavement and Schizophrenia: A Nationwide Cohort Study in Denmark and Sweden. <b>2016</b> , 95, e2434	9
1021	Excess mortality due to depression and anxiety in the United States: results from a nationally representative survey. <b>2016</b> , 39, 39-45	77
1020	Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France. <b>2016</b> , 34, 363-91	31
1019	Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. <b>2016</b> , 3, 350-7	77
1018	Impact of antipsychotic medication on transcranial direct current stimulation (tDCS) effects in schizophrenia patients. <b>2016</b> , 235, 97-103	31
1017	Influence of DAOA and RGS4 genes on the risk for psychotic disorders and their associated executive dysfunctions: A family-based study. <b>2016</b> , 32, 42-7	4

1016	NMDA receptor antagonism by repetitive MK801 administration induces schizophrenia-like structural changes in the rat brain as revealed by voxel-based morphometry and diffusion tensor imaging. <b>2016</b> , 322, 221-33	15
1015	Exercise may benefit patients with schizophrenia. <b>2016</b> , 14, 103-114	5
1014	Deficits in GABAA receptor function and working memory in non-smokers with schizophrenia. <b>2016</b> , 171, 125-30	13
1013	Inflammatory evidence for the psychosis continuum model. <b>2016</b> , 67, 189-97	30
1012	Psychotic Experiences and Neuropsychological Functioning in a Population-based Sample. <b>2016</b> , 73, 129-38	29
1011	Sex/gender differences in the brain and cognition in schizophrenia. <b>2016</b> , 67, 57-78	129
1010	Sex differences in animal models of schizophrenia shed light on the underlying pathophysiology. <b>2016</b> , 67, 41-56	36
1009	Can Psychological, Social and Demographical Factors Predict Clinical Characteristics Symptomatology of Bipolar Affective Disorder and Schizophrenia?. <b>2016</b> , 87, 501-13	4
1008	Common variants on 17q25 and gene-gene interactions conferring risk of schizophrenia in Han Chinese population and regulating gene expressions in human brain. <b>2016</b> , 21, 1244-50	11
1007	The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats. <b>2016</b> , 233, 1045-54	31
1006	Disruptions of sensorimotor gating, cytokines, glycemia, monoamines, and genes in both sexes of rats reared in social isolation can be ameliorated by oral chronic quetiapine administration. <b>2016</b> , 51, 119-130	22
1005	Health Conditions and Functional Status in Adults with Autism: A Cross-Sectional Evaluation. <b>2016</b> , 31, 77-84	72
1004	Common alleles contribute to schizophrenia in CNV carriers. <b>2016</b> , 21, 1085-9	56
1003	Regulation of Brain-Derived Neurotrophic Factor Exocytosis and Gamma-Aminobutyric Acidergic Interneuron Synapse by the Schizophrenia Susceptibility Gene Dysbindin-1. <b>2016</b> , 80, 312-322	26
1002	Sex differences in neurodevelopmental and neurodegenerative disorders: Focus on microglial function and neuroinflammation during development. <b>2016</b> , 160, 127-33	181
1001	What do the general population know, believe and feel about individuals with autism and schizophrenia: Results from a comparative survey in Denmark. <b>2016</b> , 20, 496-508	29
1000	Cognitive Behavioral Therapy Compared with Non-specialized Therapy for Alleviating the Effect of Auditory Hallucinations in People with Reoccurring Schizophrenia: A Systematic Review and Meta-analysis. <b>2017</b> , 53, 127-133	15
999	Psychometric Properties of Self-Care Requisites Scale (SCRS-h) in Hospitalized Patients Diagnosed With Schizophrenia. <b>2017</b> , 53, 16-28	1

998	Murder and psychosis: Neuropsychological profiles of homicide offenders with schizophrenia. <b>2017</b> , 27, 146-161	14
997	Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. <b>2017</b> , 29, 278-290	19
996	Correlated expression analysis of genes implicated in schizophrenia: Identification of putative disease-related pathways. <b>2017</b> , 3, 224	1
995	Establishment of a schizophrenic animal model through chronic administration of MK-801 in infancy and social isolation in childhood. <b>2017</b> , 46, 135-143	6
994	The early growth response protein 1-miR-30a-5p-neurogenic differentiation factor 1 axis as a novel biomarker for schizophrenia diagnosis and treatment monitoring. <b>2017</b> , 7, e998	37
993	Variability of 128 schizophrenia-associated gene variants across distinct ethnic populations. <b>2017</b> , 7, e988	16
992	First Presentation With Psychotic Symptoms in a Population-Based Sample. <b>2017</b> , 68, 456-461	43
991	Association of polygenic risk for major psychiatric illness with subcortical volumes and white matter integrity in UK Biobank. <b>2017</b> , 7, 42140	70
990	Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. <b>2017</b> , 4, 295-301	458
989	Trans-generation enrichment of clozapine-responsiveness trait in mice using a subchronic hypo-glutamatergic model of schizophrenia:A preliminary study. <b>2017</b> , 323, 141-145	2
988	The DAOA gene is associated with schizophrenia in the Taiwanese population. <b>2017</b> , 252, 201-207	5
987	Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders. <b>2017</b> , 267, 391-402	11
986	Persistent Serious Mental Illness Among Former Applicants for VA PTSD Disability Benefits and Long-Term Outcomes: Symptoms, Functioning, and Employment. <b>2017</b> , 30, 36-44	8
985	Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments. <b>2017</b> , 75, 157-165	56
984	No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. <b>2017</b> , 136, 52-62	24
983	Feasibility and acceptability of post-hospitalization ecological momentary assessment in patients with psychotic-spectrum disorders. <b>2017</b> , 74, 204-213	18
982	Immune activation in lactating dams alters sucklings' brain cytokines and produces non-overlapping behavioral deficits in adult female and male offspring: A novel neurodevelopmental model of sex-specific psychopathology. <b>2017</b> , 63, 35-49	24
981	Blonanserin versus risperidone for schizophrenia. <b>2017</b> ,	78

980	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. <b>2017</b> , 32, 235-248	16
979	Multi-center machine learning in imaging psychiatry: A meta-model approach. <b>2017</b> , 155, 10-24	30
978	Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward. <b>2017</b> , 80, 36-56	50
977	International trends in clozapine use: a study in 17 countries. <b>2017</b> , 136, 37-51	120
976	Judgment of moral and social transgression in schizophrenia. <b>2017</b> , 76, 160-168	3
975	Exploring non-stationarity patterns in schizophrenia: neural reorganization abnormalities in the alpha band. <b>2017</b> , 14, 046001	21
974	Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria. <b>2017</b> , 7, 3-10	7
973	[Disability Pension and Productivity Loss in Schizophrenia - An Empirical Analysis of the Financial Burden in Germany]. <b>2017</b> , 44, 93-98	2
972	Risk of developing psoriasis in patients with schizophrenia: a nationwide retrospective cohort study. <b>2017</b> , 31, 1497-1504	18
971	Hormesis, cellular stress response and neuroinflammation in schizophrenia: Early onset versus late onset state. <b>2017</b> , 95, 1182-1193	30
970	Gender differences in the structural connectome of the teenage brain revealed by generalized q-sampling MRI. <b>2017</b> , 15, 376-382	24
969	QKI6B mRNA levels are upregulated in schizophrenia and predict GFAP expression. <b>2017</b> , 1669, 63-68	6
968	Melatonin Receptor 1B Gene Polymorphisms, Haplotypes and Susceptibility to Schizophrenia. <b>2017</b> , 25, 125-133	
967	Clozapine dose for schizophrenia. <b>2017</b> , 6, CD009555	21
966	The 'cognitive footprint' of psychiatric and neurological conditions: cross-sectional study in the UK Biobank cohort. <b>2017</b> , 135, 593-605	11
965	Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. <b>2017</b> , 34, 1036-1048	29
964	Pre-clinical investigation of Diabetes Mellitus as a risk factor for schizophrenia. <b>2017</b> , 326, 154-164	1
963	Research in Clinical Pragmatics. <b>2017</b> ,	15

962	Dysregulation of Specialized Delay/Interference-Dependent Working Memory Following Loss of Dysbindin-1A in Schizophrenia-Related Phenotypes. <b>2017</b> , 42, 1349-1360	14
961	Metabolic Response to Olanzapine in Healthy Chinese Subjects with rs7093146 Polymorphism in Transcription Factor 7-like 2 Gene (TCF7L2): A Prospective Study. <b>2017</b> , 120, 601-609	1
960	Psychiatric Care in Severe Obesity. <b>2017</b> ,	1
959	Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. <b>2017</b> , 10, CD011707	2
958	Fluphenazine (dose) for people with schizophrenia. <b>2017</b> ,	78
957	Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats. <b>2017</b> , 20, 1005-1012	12
956	Disruption of Conscious Access in Schizophrenia. <b>2017</b> , 21, 878-892	26
955	TESTING HIGH-DIMENSIONAL COVARIANCE MATRICES, WITH APPLICATION TO DETECTING SCHIZOPHRENIA RISK GENES. <b>2017</b> , 11, 1810-1831	10
954	Yoga versus non-standard care for schizophrenia. <b>2017</b> , 9, CD012052	10
953	Comparing three-year extension of early intervention service to regular care following two years of early intervention service in first-episode psychosis: a randomized single blind clinical trial. <b>2017</b> , 16, 278-286	48
952	Use of HepG2 cell line for evaluation of toxic and metabolic antipsychotic action. <b>2017</b> , 11, 405-415	6
951	Experiences of stigma among family members of persons living with schizophrenia: a systematic review protocol. <b>2017</b> , 15, 1575-1584	4
950	Accumulation of minor alleles and risk prediction in schizophrenia. <b>2017</b> , 7, 11661	10
949	Population Base Rates and Disease Course of Common Psychiatric and Neurodegenerative Disorders. <b>2017</b> , 27, 284-301	7
948	Do antipsychotic drugs lose their efficacy for relapse prevention over time?. <b>2017</b> , 211, 127-129	24
947	Neuromodulation for Psychiatric Disorders. <b>2017</b> , 287-301	
946	Magnetic seizure therapy for people with schizophrenia. <b>2017</b> ,	78
945	International trends in antipsychotic use: A study in 16 countries, 2005-2014. <b>2017</b> , 27, 1064-1076	112

944	Methylene blue and its analogues as antidepressant compounds. <b>2017</b> , 32, 1357-1382	24
943	Mind the Gap: Developing an Integrated Behavioral Health Home to Address Health Disparities in Serious Mental Illness. <b>2017</b> , 68, 1217-1224	15
942	Mimetic Theory and the evolutionary paradox of schizophrenia: The archetypal scapegoat hypothesis. <b>2017</b> , 108, 101-107	4
941	Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-naïve first-episode schizophrenia patients. <b>2017</b> , 95, 91-101	2
940	Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment. <b>2017</b> , 27, 884-891	13
939	Exploring service users', carers' and professionals' perspectives and experiences of current antipsychotic prescribing: A qualitative study. <b>2017</b> , 13, 275-287	15
938	The Effects of Recreation Therapy on the Habit of Smoking and Positive/Negative Symptoms Among Patients with Chronic Schizophrenia. <b>2017</b> , 44, 31-35	
937	Diagnostic value of blood-derived microRNAs for schizophrenia: results of a meta-analysis and validation. <b>2017</b> , 7, 15328	35
936	Some Thoughts About Racial Disparities. <b>2017</b> , 37, 641-645	
935	Association of transcription factor 4 (TCF4) gene mRNA level with schizophrenia, its psychopathology, intelligence and cognitive impairments. <b>2017</b> , 31, 344-351	4
934	Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse. <b>2017</b> , 39, 1380-1395.e4	15
933	Antipsychotic combinations for schizophrenia. <b>2017</b> , 6, CD009005	20
932	Rural versus urban perspectives on behavioral health issues and priorities. <b>2017</b> , 48, 515-526	1
931	Genetic Basis of Positive and Negative Symptom Domains in Schizophrenia. <b>2017</b> , 19, 559-575	10
930	Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms. <b>2017</b> , 47, 19-33	49
929	Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain. <b>2017</b> , 20, 1039-1047	15
928	Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial. <b>2017</b> , 94, 70-77	6
927	Dental caries status of patients with schizophrenia in Seville, Spain: a case-control study. <b>2017</b> , 10, 50	11

926	Wendan decoction (Traditional Chinese medicine) for schizophrenia. <b>2017</b> , 6, CD012217	7
925	Estrogen Signaling as a Therapeutic Target in Neurodevelopmental Disorders. <b>2017</b> , 360, 48-58	39
924	Modeling Schizophrenia: Focus on Developmental Models. <b>2017</b> , 369-388	2
923	Traditional Chinese medicine for schizophrenia: A survey of randomized trials. <b>2017</b> , 9, e12265	5
922	Unraveling the genetic architecture of copy number variants associated with schizophrenia and other neuropsychiatric disorders. <b>2017</b> , 95, 1144-1160	24
921	Paternal age and psychiatric disorders: A review. <b>2017</b> , 174, 202-213	43
920	Cognitive Performance Among Carriers of Pathogenic Copy Number Variants: Analysis of 152,000 UK Biobank Subjects. <b>2017</b> , 82, 103-110	91
919	Mitochondrial dysfunction in a family with psychosis and chronic fatigue syndrome. <b>2017</b> , 34, 1-8	6
918	Serum gamma-glutamyltransferase is associated with future risk of psychosis - A prospective cohort study. <b>2017</b> , 181, 72-74	4
917	Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. <b>2017</b> , 19, 162-171	33
916	Tone-matching ability in patients with schizophrenia: A systematic review and meta-analysis. <b>2017</b> , 181, 94-99	15
915	MK-801-induced impairments on the trial-unique, delayed nonmatching-to-location task in rats: effects of acute sodium nitroprusside. <b>2017</b> , 234, 211-222	15
914	Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. <b>2017</b> , 183, 10-21	48
913	A review of molecular genetic studies of neurocognitive deficits in schizophrenia. <b>2017</b> , 72, 50-67	32
912	The impact of gender on treatment effectiveness of body psychotherapy for negative symptoms of schizophrenia: A secondary analysis of the NESS trial data. <b>2017</b> , 247, 73-78	9
911	Perforated appendicitis in patients with schizophrenia: a retrospective cohort study. <b>2017</b> , 7, e017150	5
910	Subchronic olanzapine exposure leads to increased expression of myelination-related genes in rat fronto-medial cortex. <b>2017</b> , 7, 1262	10
909	Video games for schizophrenia. <b>2017</b> ,	78



908	Yoga as part of a package of care versus non-standard care for schizophrenia. <b>2017,</b>	2
907	Chlorpromazine versus lithium for people with schizophrenia. <b>2017,</b>	78
906	Prevalence of Metabolic Syndrome in the Hospitalized Psychiatric Patients. <b>2017, 71, 412-416</b>	1
905	Abnormal Psychology in Context: The Australian and New Zealand Handbook. 76-93	
904	Vitamin-D Deficiency As a Potential Environmental Risk Factor in Multiple Sclerosis, Schizophrenia, and Autism. <b>2017, 8, 47</b>	40
903	Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of , and Variants with Negative Symptoms and Cognitive Deficits. <b>2017, 8, 292</b>	11
902	Biological and Social Causation of Serious Mental Illness. <b>2017, 431-449</b>	
901	Pathophysiological Role of Purines and Pyrimidines in Neurodevelopment: Unveiling New Pharmacological Approaches to Congenital Brain Diseases. <b>2017, 8, 941</b>	45
900	Abnormally Increased Secretion in Olfactory Neuronal Precursors from a Case of Schizophrenia Is Modulated by Melatonin: A Pilot Study. <b>2017, 18,</b>	7
899	Neuroimmune Interactions in Schizophrenia: Focus on Vagus Nerve Stimulation and Activation of the Alpha-7 Nicotinic Acetylcholine Receptor. <b>2017, 8, 618</b>	26
898	Genetics of Aggression in Alzheimer's Disease (AD). <b>2017, 9, 87</b>	12
897	Effect of Neuroinflammation on Synaptic Organization and Function in the Developing Brain: Implications for Neurodevelopmental and Neurodegenerative Disorders. <b>2017, 11, 190</b>	55
896	Use of transcranial direct current stimulation for the treatment of auditory hallucinations of schizophrenia - a systematic review. <b>2017, 13, 347-355</b>	21
895	"I cry every day and night, I have my son tied in chains": physical restraint of people with schizophrenia in community settings in Ethiopia. <b>2017, 13, 47</b>	54
894	Recognition of early-onset schizophrenia using deep-learning method. <b>2017, 4,</b>	15
893	Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-one (TAK-915), for the Treatment of Cognitive Disorders. <b>2017, 65, 1058-1077</b>	9
892	Can Models of Reinforcement Learning Help Us to Understand Symptoms of Schizophrenia?. <b>2017, 261-275</b>	
891	Tumor necrosis factor- $\alpha$ and - $\beta$ genetic polymorphisms as a risk factor in Saudi patients with schizophrenia. <b>2017, 13, 1081-1088</b>	8

890	Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. <b>2017</b> , 13, 2767-2779	16
889	Efficacy of Task Centered Group Work Intervention in Schizophrenia Patients. <b>2017</b> , 20,	2
888	Schizophrenia. <b>2017</b> , 1370-1379.e5	2
887	Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. <b>2018</b> , 50, 381-389	787
886	The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia. <b>2018</b> , 38, 31-36	34
885	Estradiol and luteinizing hormone regulate recognition memory following subchronic phencyclidine: Evidence for hippocampal GABA action. <b>2018</b> , 91, 86-94	7
884	Introducing Specialist Integrated Mental Health Care in Lebanon: The Psychosis Recovery Outreach Program. <b>2018</b> , 69, 738-740	4
883	Social Determinants of Health and Preclinical Glycemic Control in Newly Diagnosed First-Episode Psychosis Patients. <b>2018</b> , 63, 547-556	11
882	Schizophrenia and Criminal Responsibility: A Systematic Review. <b>2018</b> , 206, 370-377	6
881	Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study. <b>2018</b> , 267, 56-62	17
880	d-Serine administration affects nitric oxide synthase 1 adaptor protein and DISC1 expression in sex-specific manner. <b>2018</b> , 89, 20-32	5
879	Consanguineous Marriage and the Psychopathology of the Progeny of First-Cousin Couples. <b>2018</b> , 75, 426-427	1
878	Cannabidiol as a Potential Novel Therapeutic Agent for Psychotic Disorders. <b>2018</b> , 309-339	1
877	Network Neuroscience: A Framework for Developing Biomarkers in Psychiatry. <b>2018</b> , 40, 79-109	14
876	Sexually dimorphic subcortical brain volumes in emerging psychosis. <b>2018</b> , 199, 257-265	9
875	Mental Illness as a Putative Risk Factor for Violence and Aggression. <b>2018</b> , 531-552	2
874	Treatment of antisocial personality disorder: Development of a practice focused framework. <b>2018</b> , 58, 72-78	9
873	Serum nerve growth factor beta, brain- and glial-derived neurotrophic factor levels and psychopathology in unmedicated patients with schizophrenia. <b>2018</b> , 81, 577-581	5

872	Direct healthcare cost of schizophrenia - European overview. <b>2018</b> , 48, 79-92	14
871	Association of Polygenic Risk for Attention-Deficit/Hyperactivity Disorder With Co-occurring Traits and Disorders. <b>2018</b> , 3, 635-643	45
870	Association between celiac disease and schizophrenia: a meta-analysis. <b>2018</b> , 30, 442-446	10
869	Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. <b>2018</b> , 137, 88-97	71
868	Effects of chlorpromazine on sleep quality, clinical and emotional measures among patients with schizophrenia. <b>2018</b> , 165, 134-138	4
867	Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset. <b>2018</b> , 28, 24-36	12
866	Analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015. <b>2018</b> , 12, 9	4
865	A quantitative analysis of antipsychotic prescribing trends for the treatment of schizophrenia in England and Wales. <b>2018</b> , 9, 2054270418758570	14
864	Health conditions, functional status and health care utilization in adults with cerebral palsy. <b>2018</b> , 35, 661-670	22
863	Mobile cognitive testing in patients with schizophrenia: A controlled study of feasibility and validity. <b>2018</b> , 28, 204-213	6
862	Monocausal Attributions Along Cross-Sections of Psychosis Development and Links with Psychopathology and Data Gathering Style. <b>2018</b> , 42, 699-710	2
861	A systematic review of clozapine-induced myocarditis. <b>2018</b> , 259, 122-129	50
860	Comparisons of schizotypal traits across 12 countries: Results from the International Consortium for Schizotypy Research. <b>2018</b> , 199, 128-134	21
859	Sex and Diffusion Tensor Imaging of White Matter in Schizophrenia: A Systematic Review Plus Meta-analysis of the Corpus Callosum. <b>2018</b> , 44, 203-221	19
858	Epidemiology of pain and relation to psychiatric disorders. <b>2018</b> , 87, 159-167	80
857	Cardiorespiratory fitness is associated with reduced risk of future psychosis: A long-term prospective cohort study. <b>2018</b> , 192, 473-474	6
856	Polygenic risk scores for schizophrenia and bipolar disorder associate with addiction. <b>2018</b> , 23, 485-492	58
855	Schizophr�nie et troubles du comportement alimentaire : synth�se de la littfature. <b>2018</b> , 176, 231-235	

854	Comparative genomic evidence for the involvement of schizophrenia risk genes in antipsychotic effects. <b>2018</b> , 23, 708-712	20
853	Physical activity correlates among people with psychosis: Data from 47 low- and middle-income countries. <b>2018</b> , 193, 412-417	18
852	Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia. <b>2018</b> , 193, 139-145	16
851	Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology. <b>2018</b> , 235, 447-458	18
850	Decreased value-sensitivity in schizophrenia. <b>2018</b> , 259, 295-301	9
849	Dynamic Functional Connectivity States Reflecting Psychotic-like Experiences. <b>2018</b> , 3, 443-453	27
848	Psychotic patients who used cannabis frequently before illness onset have higher genetic predisposition to schizophrenia than those who did not. <b>2018</b> , 48, 43-49	13
847	Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases. <b>2018</b> , 641, 25-34	22
846	Average spectral power changes at the hippocampal electroencephalogram in schizophrenia model induced by ketamine. <b>2018</b> , 32, 60-68	6
845	The role of cadherin genes in five major psychiatric disorders: A literature update. <b>2018</b> , 177, 168-180	29
844	High C-reactive protein levels are associated with depressive symptoms in schizophrenia. <b>2018</b> , 225, 671-675	23
843	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. <b>2018</b> , 75, 36-46	154
842	The association between Borna Disease Virus and schizophrenia: A systematic review and meta-analysis. <b>2018</b> , 34, 67-73	7
841	Metabolic syndrome in drug naïve schizophrenic patients. <b>2018</b> , 12, 135-140	12
840	Mortality, morbidity and medical resources utilization of patients with schizophrenia: A case-control community-based study. <b>2018</b> , 260, 177-181	23
839	Effectiveness and cost-effectiveness of an integrated care program for schizophrenia: an analysis of routine data. <b>2018</b> , 268, 611-619	1
838	The maturation of speech structure in psychosis is resistant to formal education. <b>2018</b> , 4, 25	16
837	The Association of Pre-stroke Psychosis and Post-stroke Levels of Health, Resource Utilization, and Care Process: A Register-Based Study. <b>2018</b> , 9, 1042	7

836	Duration of Untreated Psychosis: An Important Prognostic Indicator. <b>2018</b> , 03,	
835	Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. <b>2018</b> , 10, CD012398	2
834	Yoga for schizophrenia. <b>2018</b> ,	78
833	Risikofaktoren für die Entstehung und den Verlauf der Schizophrenie. <b>2018</b> , 12, 467-481	
832	Sauna Bathing and Risk of Psychotic Disorders: A Prospective Cohort Study. <b>2018</b> , 27, 562-569	5
831	Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review. <b>2018</b> , 43, 223-244	26
830	Studying and modulating schizophrenia-associated dysfunctions of oligodendrocytes with patient-specific cell systems. <b>2018</b> , 4, 23	21
829	A systematic review of the indirect costs of schizophrenia in Europe. <b>2018</b> , 28, 1043-1049	13
828	Schizophrenia-associated mt-DNA SNPs exhibit highly variable haplogroup affiliation and nuclear ancestry: Bi-genomic dependence raises major concerns for link to disease. <b>2018</b> , 13, e0208828	5
827	, a Candidate Gene for Psychiatric and Neurological Disorders. <b>2018</b> , 4, 119-133	22
826	The association between neonatal vitamin D status and risk of schizophrenia. <b>2018</b> , 8, 17692	49
825	Genetic recovery of ErbB4 in adulthood partially restores brain functions in null mice. <b>2018</b> , 115, 13105-13110	20
824	DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder. <b>2018</b> , 19,	22
823	Perspectives and Experiences of Primary Caregivers of Individuals with Schizophrenia in Thailand. <b>2018</b> , 39, 858-864	8
822	EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). <b>2018</b> , 54, 124-144	197
821	New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders. <b>2018</b> , 5,	21
820	Informal Caregiving Relationships in Psychosis: Reviewing the Impact of Patient Violence on Caregivers. <b>2018</b> , 9, 1530	12
819	The Olfactory System: Part III: Central Processing of Olfaction and Central Olfactory Dysfunction. <b>2018</b> , 8, 298-316	0

818	Gender differences in social functioning in people with schizophrenia in psychosocial rehabilitation services using one-dimensional and multidimensional instruments. <b>2018</b> , 87, 120-122	4
817	Perceptions of the causes of schizophrenia and associated factors by the Holy Trinity Theological College students in Ethiopia. <b>2018</b> , 17, 43	2
816	Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis. <b>2018</b> , 28, 1360-1370	18
815	Nicotinamide-N-methyltransferase controls behavior, neurodegeneration and lifespan by regulating neuronal autophagy. <b>2018</b> , 14, e1007561	19
814	Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome. <b>2018</b> , 176, 2182-2191	36
813	Schizophrenia and Exercise. <b>2018</b> , 65-82	
812	A comparative study of the typical toxic metals in serum by patients of schizophrenia and healthy controls in China. <b>2018</b> , 269, 558-564	4
811	Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis. <b>2018</b> , 32, 1011-1023	14
810	Convergence of placenta biology and genetic risk for schizophrenia. <b>2018</b> , 24, 792-801	141
809	Sex and gender differences in schizophrenic psychoses-a critical review. <b>2018</b> , 21, 627-648	80
808	Association of Urbanicity With Psychosis in Low- and Middle-Income Countries. <b>2018</b> , 75, 678-686	83
807	Changes in behavioural parameters, oxidative stress and neurotrophins in the brain of adult offspring induced to an animal model of schizophrenia: The effects of FA deficient or FA supplemented diet during the neurodevelopmental phase. <b>2018</b> , 86, 52-64	14
806	Suicide Prevention. <b>2018</b> ,	1
805	Cause, consequence or coincidence: The relationship between psychiatric disease and metabolic syndrome. <b>2018</b> , 1, 23-38	1
804	Changes in antipsychotic drug usage and factors affecting the use of typical drugs based on nationwide health insurance data in South Korea. <b>2018</b> , 8, e020280	6
803	The Effects of Music Intervention on Functional Connectivity Strength of the Brain in Schizophrenia. <b>2018</b> , 2018, 2821832	15
802	Low plasma concentrations of N-methyl-d-aspartate receptor subunits as a possible biomarker for psychosis. <b>2018</b> , 202, 55-63	6
801	The development and evaluation of a computerized decision aid for the treatment of psychotic disorders. <b>2018</b> , 18, 163	7

800	The relationship between serum cytokine levels and degree of psychosis in patients with schizophrenia. <b>2018</b> , 268, 467-472	27
799	Magnetic Seizure Therapy in Treatment-Resistant Schizophrenia: A Pilot Study. <b>2017</b> , 8, 310	12
798	Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment. <b>2018</b> , 6, 166	11
797	Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study. <b>2018</b> , 18, 249	2
796	Deficits in physiological and self-conscious emotional response to errors in hoarding disorder. <b>2018</b> , 268, 157-164	4
795	Aspects of Additional Psychiatric Disorders in Severe Depression/Melancholia: A Comparison between Suicides and Controls and General Pattern. <b>2018</b> , 15,	1
794	Psychotherapeutische Behandlungsansätze bei Psychosen. <b>2018</b> , 63, 329-347	
793	Evaluating patient satisfaction with pharmacist-administered long-acting injectable antipsychotics in the community pharmacy. <b>2018</b> , 58, S24-S29.e2	12
792	First Presentation with Psychotic Symptoms to the Emergency Department. <b>2018</b> , 55, 78-86	5
791	The relationship between quality of life and physical fitness in people with severe mental illness. <b>2018</b> , 16, 82	7
790	Frontal dysconnectivity in 22q11.2 deletion syndrome: an atlas-based functional connectivity analysis. <b>2018</b> , 14, 2	15
789	EZH1 is an antipsychotic-sensitive epigenetic modulator of social and motivational behavior that is dysregulated in schizophrenia. <b>2018</b> , 119, 149-158	6
788	A Review of the Effects of Transcranial Direct Current Stimulation for the Treatment of Hallucinations in Patients With Schizophrenia. <b>2018</b> , 34, 164-171	13
787	Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders. <b>2018</b> , 8,	82
786	[Diseases of the schizophrenia spectrum disorder in old age : Diagnostic and therapeutic challenges]. <b>2018</b> , 51, 744-750	1
785	Epidemiology of schizophrenia and risk factors of schizophrenia-associated aggression from 2011 to 2015. <b>2018</b> , 46, 4039-4049	16
784	Functioning in patients with schizophrenia: A multicentre study evaluating the clinical perspective. <b>2018</b> , 270, 1092-1098	5
783	Gut microbiome and magnetic resonance spectroscopy study of subjects at ultra-high risk for psychosis may support the membrane hypothesis. <b>2018</b> , 53, 37-45	54

782	Mirtazapine adjunct for people with schizophrenia. <b>2018</b> , 5, CD011943	3
781	Risk factors for early circulatory mortality in patients with schizophrenia. <b>2018</b> , 267, 7-11	18
780	Protective effects of <i>Spinacia oleracea</i> seeds extract in an experimental model of schizophrenia: Possible behavior, biochemical, neurochemical and cellular alterations. <b>2018</b> , 105, 1015-1025	9
779	Treatment Retention Among Patients Participating in Coordinated Specialty Care for First-Episode Psychosis: a Mixed-Methods Analysis. <b>2019</b> , 46, 415-433	5
778	Sex differences in the developing brain: insights from multimodal neuroimaging. <b>2019</b> , 44, 71-85	102
777	The schizophrenia and bipolar twin study in Sweden (STAR). <b>2019</b> , 204, 183-192	8
776	Focus on eye care in schizophrenia. <b>2019</b> , 102, 385-393	7
775	Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. <b>2019</b> , 35, 41-49	4
774	Prevalence of attention deficit hyperactivity disorder symptoms in patients with schizophrenia. <b>2019</b> , 139, 89-96	6
773	Peripheral Biomarkers for First-Episode Psychosis-Opportunities from the Neuroinflammatory Hypothesis of Schizophrenia. <b>2019</b> , 16, 177-184	14
772	Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes. <b>2019</b> , 15, 2365-2370	9
771	Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: A systematic review of the literature. <b>2019</b> , 103, 277-286	5
770	Essential genetic findings in neurodevelopmental disorders. <b>2019</b> , 13, 31	17
769	The experiences and meanings of recovery for Swazi women living with "schizophrenia". <b>2019</b> , 26, 153-162	12
768	Age Matters: an Atypical Association Between Polymorphism of MTHFR and Clinical Phenotypes in Children with Schizophrenia. <b>2019</b> , 69, 485-493	2
767	Short-term versus long-term psychotherapy for adult psychiatric disorders: a protocol for a systematic review with meta-analysis and trial sequential analysis. <b>2019</b> , 8, 169	6
766	Brain-based ranking of cognitive domains to predict schizophrenia. <b>2019</b> , 40, 4487-4507	12
765	Behavioural effects of high fat diet exposure starting in late adolescence in neuregulin 1 transmembrane domain mutant mice. <b>2019</b> , 373, 112074	2



764	Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study. <b>2019</b> , 9, 8685	10
763	The distinguishing intrinsic brain circuitry in treatment-naïve first-episode schizophrenia: Ensemble learning classification. <b>2019</b> , 365, 44-53	8
762	Lost in translational biology: Understanding sex differences to inform studies of diseases of the nervous system. <b>2019</b> , 1722, 146352	9
761	Altered Causal Coupling Pathways within the Central-Autonomic-Network in Patients Suffering from Schizophrenia. <b>2019</b> , 21,	7
760	Increased frequency of psychosis after second-generation antiepileptic drug administration in adults with focal epilepsy. <b>2019</b> , 97, 138-143	4
759	Machine learning techniques in a structural and functional MRI diagnostic approach in schizophrenia: a systematic review. <b>2019</b> , 15, 1605-1627	29
758	Paliperidone is associated with reduced risk of severe hepatic outcome in patients with schizophrenia and viral hepatitis: A nationwide population-based cohort study. <b>2019</b> , 281, 112597	3
757	The Possible Role of Telomere Length and Chemokines in the Aging Process: A Transdiagnostic Review in Psychiatry. <b>2019</b> , 15, 171-192	
756	Label-free biosensing using a microring resonator integrated with poly-(dimethylsiloxane) microfluidic channels. <b>2019</b> , 90, 035004	9
755	Cannabis and Psychosis Through the Lens of DSM-5. <b>2019</b> , 16,	10
754	Association of Childhood Exposure to Nitrogen Dioxide and Polygenic Risk Score for Schizophrenia With the Risk of Developing Schizophrenia. <b>2019</b> , 2, e1914401	17
753	Risks of psychosis in methamphetamine users: cross-sectional study in Thailand. <b>2019</b> , 9, e032711	7
752	S3-Leitlinie Schizophrenie. <b>2019</b> ,	12
751	Psychotherapeutische und psychosoziale Interventionen (Modul 4b). <b>2019</b> , 139-180	
750	Clozapine (generic versus branded) for people with schizophrenia. <b>2019</b> ,	0
749	Olanzapine dose for people with schizophrenia. <b>2019</b> ,	1
748	Global landscape and genetic regulation of RNA editing in cortical samples from individuals with schizophrenia. <b>2019</b> , 22, 1402-1412	32
747	Identifying schizophrenia subgroups using clustering and supervised learning. <b>2019</b> , 214, 51-59	16

746	Deconvolution of transcriptional networks identifies TCF4 as a master regulator in schizophrenia. <b>2019</b> , 5, eaa4139	26
745	Balancing body and mind: selecting the optimal antipsychotic. <b>2019</b> , 394, 900-902	3
744	Rising co-payments coincide with unwanted effects on continuity of healthcare for patients with schizophrenia in the Netherlands. <b>2019</b> , 14, e0222046	3
743	CommonMind Consortium provides transcriptomic and epigenomic data for Schizophrenia and Bipolar Disorder. <b>2019</b> , 6, 180	52
742	Diffusion kurtosis imaging of gray matter in schizophrenia. <b>2019</b> , 121, 201-224	8
741	Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. <b>2019</b> , 208, 420-429	16
740	Reproducible grey matter patterns index a multivariate, global alteration of brain structure in schizophrenia and bipolar disorder. <b>2019</b> , 9, 12	19
739	Does a history of violence predict higher antipsychotic dosage in schizophrenia?. <b>2019</b> , 59, 81-82	1
738	Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. <b>2019</b> , 8, 84-91	3
737	The effect of cognitive behavioral therapy for insomnia in schizophrenia patients with sleep Disturbance: A non-randomized, assessor-blind trial. <b>2019</b> , 274, 182-188	12
736	Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats. <b>2019</b> , 1719, 30-39	9
735	Risk of schizophrenia among people with obsessive-compulsive disorder: A nationwide population-based cohort study. <b>2019</b> , 209, 58-63	14
734	Long-term effects of prenatal exposure to earthquake on adult schizophrenia. <b>2019</b> , 215, 730-735	13
733	Synapse Pathology in Schizophrenia: A Meta-analysis of Postsynaptic Elements in Postmortem Brain Studies. <b>2020</b> , 46, 374-386	34
732	Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections. <b>2019</b> , 19, 393	5
731	Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria. <b>2019</b> , 33, 204-213	1
730	Speaking-Induced Suppression of the Auditory Cortex in Humans and Its Relevance to Schizophrenia. <b>2019</b> , 4, 791-804	10
729	Regional Heterogeneity in Gene Expression, Regulation, and Coherence in the Frontal Cortex and Hippocampus across Development and Schizophrenia. <b>2019</b> , 103, 203-216.e8	67

728	A New Method for Estimating Incidence of First Psychotic Diagnosis in a Medicaid Population. <b>2019</b> , 70, 665-673	5
727	Meta-analysis of genomic variants and gene expression data in schizophrenia suggests the potential need for adjunctive therapeutic interventions for neuropsychiatric disorders. <b>2019</b> , 98, 1	2
726	Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach. <b>2019</b> , 9, 8516	6
725	Interrogating the Evolutionary Paradox of Schizophrenia: A Novel Framework and Evidence Supporting Recent Negative Selection of Schizophrenia Risk Alleles. <b>2019</b> , 10, 389	9
724	Violence and Mental Illness. <b>2019</b> ,	1
723	Synaptic functions and their disruption in schizophrenia: From clinical evidence to synaptic optogenetics in an animal model. <b>2019</b> , 95, 179-197	18
722	Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study. <b>2019</b> , 276, 210-217	4
721	Ethnic density and other neighbourhood associations for mortality in severe mental illness: a retrospective cohort study with multi-level analysis from an urbanised and ethnically diverse location in the UK. <b>2019</b> , 6, 506-517	10
720	Schizophrenia in high risk opioid users: A short communication on an autopsy study. <b>2019</b> , 276, 112-114	3
719	How to serve our ethnic minority communities better. <b>2019</b> , 6, 275-277	2
718	Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. <b>2019</b> , 10, 67	35
717	Childhood Trauma in Schizophrenia: Current Findings and Research Perspectives. <b>2019</b> , 13, 274	40
716	[Risk factors for the development of schizophrenia]. <b>2019</b> , 87, 133-143	6
715	Schizophrenia and Bilingualism. <b>2019</b> , 625-654	
714	Central and Peripheral Changes in FOS Expression in Schizophrenia Based on Genome-Wide Gene Expression. <b>2019</b> , 10, 232	5
713	Cerebellar Theta Frequency Transcranial Pulsed Stimulation Increases Frontal Theta Oscillations in Patients with Schizophrenia. <b>2019</b> , 18, 489-499	13
712	Effects of adult enriched environment on cognition, hippocampal-prefrontal plasticity and NMDAR subunit expression in MK-801-induced schizophrenia model. <b>2019</b> , 29, 590-600	8
711	Risperdal CONSTA Needle Detachment. Incidence Rates Before and After Kit Redesign: A Retrospective Study using Electronic Health Records and Natural Language Processing in the Department of Veterans Affairs. <b>2019</b> , 8, 95-108	1

710	One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects. <b>2019</b> , 22, 358-369	10
709	Clinical characteristics and prognosis in patients with chronic thromboembolic pulmonary hypertension and a concomitant psychiatric disorder. <b>2019</b> , 9, 2045894019836420	4
708	The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the NMDA receptor antagonist ketamine in rats. <b>2019</b> , 151, 74-83	13
707	Varenicline: Treating Smoking Addiction and Schizophrenia. <b>2019</b> , 467-474	
706	Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism. <b>2019</b> , 176, 477-486	21
705	A Machine Learning Approach for the Automatic Classification of Schizophrenic Discourse. <b>2019</b> , 7, 45544-45553	
704	Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life. <b>2019</b> , 276, 1-5	4
703	Transgenerational Interaction of Alzheimer's Disease with Schizophrenia through Amyloid Evolvability. <b>2019</b> , 68, 473-481	9
702	Low-rank network signatures in the triple network separate schizophrenia and major depressive disorder. <b>2019</b> , 22, 101725	11
701	Role of basal ganglia neurocircuitry in the pathology of psychiatric disorders. <b>2019</b> , 73, 289-301	23
700	Sensory-targeted cognitive training for schizophrenia. <b>2019</b> , 19, 211-225	2
699	Telomeres in neurological disorders. <b>2019</b> , 90, 81-132	17
698	Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. <b>2019</b> , 236, 1985-1997	20
697	Effects of sodium nitroprusside in the acute dizocilpine (MK-801) animal model of schizophrenia. <b>2019</b> , 147, 140-147	5
696	: a novel potential diagnostic and therapeutic biomarker for schizophrenia. <b>2019</b> , 13, 331-340	16
695	Classification of Schizophrenia by Iterative Random Forest Feature Selection Based on DNA Methylation Array Data. <b>2019</b> ,	1
694	Dying Too Soon: Excess Mortality in Severe Mental Illness. <b>2019</b> , 10, 855	18
693	Phenomenology of Impulsive Aggression and Intermittent Explosive Disorder. <b>2019</b> , 37-65	4

692	Clozapine for persistent aggressive behaviour or agitation in people with schizophrenia. <b>2019,</b>	78
691	Scaling up Prediction of Psychosis by Natural Language Processing. <b>2019,</b>	1
690	Blockade of multiple monoamines receptors reduce insulin secretion from pancreatic $\beta$ cells. <b>2019,</b> 9, 16438	6
689	Electroconvulsive therapy for treatment-resistant schizophrenia. <b>2019,</b> 3, CD011847	13
688	Haloperidol discontinuation for people with schizophrenia. <b>2019,</b> 4, CD011408	5
687	Humour-based interventions for people with schizophrenia. <b>2019,</b>	1
686	Haloperidol versus olanzapine for people with schizophrenia. <b>2019,</b>	78
685	Glutathione Deficiency and Alterations in the Sulfur Amino Acid Homeostasis during Early Postnatal Development as Potential Triggering Factors for Schizophrenia-Like Behavior in Adult Rats. <b>2019,</b> 24,	8
684	Experiences of Hospitalization of Patients With Psychotic Disorders on Medical-Surgical Units: A Thematic Analysis. <b>2021,</b> 27, 306-321	2
683	Yoga as part of a package of care versus non-standard care for schizophrenia. <b>2019,</b> 4, CD012807	2
682	1,25-Dihydroxyvitamin D modulates L-type voltage-gated calcium channels in a subset of neurons in the developing mouse prefrontal cortex. <b>2019,</b> 9, 281	9
681	A telemedicine platform to improve clinical parameters in paranoid schizophrenia patients: Results of a one-year randomized study. <b>2019,</b> 204, 389-396	12
680	Burden for Parents of Patients With Schizophrenia-A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls. <b>2019,</b> 45, 794-803	11
679	The association between comorbid psychiatric diagnoses and hospitalization-related factors among individuals with schizophrenia. <b>2019,</b> 89, 7-15	11
678	A meta-analysis of transcranial direct current stimulation for schizophrenia: "Is more better?". <b>2019,</b> 110, 117-126	23
677	Early intervention for depression in young people: a blind spot in mental health care. <b>2019,</b> 6, 267-272	35
676	Treatment resistant schizophrenia - review and a call to action. <b>2019,</b> 36, 279-291	22
675	Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment. <b>2019,</b> 20, 11-24	13

674	A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis. <b>2019</b> , 45, 1120-1133	61
673	Evaluation of ultrasonic vocalizations in a neurodevelopmental model of schizophrenia during the early life stages of rats. <b>2019</b> , 146, 28-38	10
672	Cognitive functions associated with developing prefrontal cortex during adolescence and developmental neuropsychiatric disorders. <b>2019</b> , 131, 104322	16
671	Gender differences among homicide offenders with schizophrenia in Hunan Province, China. <b>2019</b> , 271, 124-130	7
670	Neutrophil/lymphocyte, platelet/lymphocyte and monocyte/lymphocyte ratios in different stages of schizophrenia. <b>2019</b> , 271, 131-135	27
669	Sex- and age-related changes in GABA signaling components in the human cortex. <b>2019</b> , 10, 5	32
668	Comparing disease-specific and generic quality of life measures in patients with schizophrenia. <b>2019</b> , 273, 387-393	9
667	A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. <b>2019</b> , 24, 328-337	18
666	Gender differences in the prevalence, comorbidities and antipsychotic prescription of early-onset schizophrenia: a nationwide population-based study in Taiwan. <b>2019</b> , 28, 759-767	9
665	Optimizing Mental Health Treatment for Emerging Adults with First-Episode Psychosis. <b>2019</b> , 4, 157-169	2
664	Estimating the incidence of first-episode psychosis using population-based health administrative data to inform early psychosis intervention services. <b>2019</b> , 49, 2091-2099	19
663	A Naturalistic Study of Racial Disparities in Diagnoses at an Outpatient Behavioral Health Clinic. <b>2019</b> , 70, 130-134	43
662	Mental Health in Chronic and End-Stage Renal Disease. <b>2019</b> , 73-89	
661	Comparison of serum essential trace metals between patients with schizophrenia and healthy controls. <b>2019</b> , 51, 79-85	22
660	Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications. <b>2020</b> , 5, 1-26	17
659	How to control for confounds in decoding analyses of neuroimaging data. <b>2019</b> , 184, 741-760	39
658	Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium. <b>2019</b> , 204, 96-103	21
657	Retrospective study of first episode psychosis in the Dublin Southwest Mental Health Service: demographics, clinical profile and service evaluation of treatment. <b>2019</b> , 36, 249-258	3

656	[Impact of duration of untreated psychosis on quality of life and cognitive functions]. <b>2019</b> , 45, 22-26	2
655	'False-positive' self-reported psychotic experiences in the general population: an investigation of outcome, predictive factors and clinical relevance. <b>2019</b> , 28, 532-543	17
654	From manageable to losing control: a grounded theory study of psychosis risk syndrome. <b>2019</b> , 13, 574-581	
653	Predicting the Self: Lessons from Schizophrenia. <b>2019</b> , 10, 381-400	1
652	Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia patients. <b>2020</b> , 270, 425-431	3
651	Dysregulated Prefrontal Cortical RhoA Signal Transduction in Bipolar Disorder with Psychosis: New Implications for Disease Pathophysiology. <b>2020</b> , 30, 59-71	2
650	Assessing Reality Testing in Mice Through Dopamine-Dependent Associatively Evoked Processing of Absent Gustatory Stimuli. <b>2020</b> , 46, 54-67	7
649	Cortico-thalamic dysconnection in early-stage schizophrenia: a functional connectivity magnetic resonance imaging study. <b>2020</b> , 270, 351-358	3
648	Predicting psychosis-spectrum diagnoses in adulthood from social behaviors and neighborhood contexts in childhood. <b>2020</b> , 32, 465-479	10
647	Behavioural effects of high fat diet in adult Nrg1 type III transgenic mice. <b>2020</b> , 377, 112217	5
646	Detecting schizophrenia early: Prediagnosis healthcare utilization characteristics of patients with schizophrenia may aid early detection. <b>2020</b> , 215, 392-398	3
645	Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis. <b>2020</b> , 46, 505-516	31
644	Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole. <b>2020</b> , 237, 167-175	2
643	Cross-Validation of the Arabic Mini International Neuropsychiatric Interview, Module K, for Diagnosis of Schizophrenia and the Arabic Positive and Negative Syndrome Scale. <b>2020</b> , 42, 139-149	1
642	Gender differences in early onset of chronic physical multimorbidities in schizophrenia spectrum disorder: Do women suffer more?. <b>2020</b> , 14, 418-427	10
641	Sleep therapeutics and neuropsychiatric illness. <b>2020</b> , 45, 166-175	11
640	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. <b>2020</b> , 226, 44-51	14
639	Sex differences in symptomatology of psychosis-risk patients and in prediction of psychosis. <b>2020</b> , 23, 339-349	5

638	Reliability of police reports when assessing health information at the forensic post-mortem examination-using schizophrenia as a model. <b>2020</b> , 134, 1195-1201	
637	The prevalence of Dissociative Disorders and dissociative experiences in college populations: a meta-analysis of 98 studies. <b>2020</b> , 21, 16-61	21
636	Relationship between metabolic syndrome and acylated/desacylated ghrelin ratio in patients with schizophrenia under olanzapine medication. <b>2020</b> , 34, 86-92	6
635	Cognitive performance of the MAM-E17 schizophrenia model rats in different age-periods. <b>2020</b> , 379, 112345	1
634	Genetics of Childhood-onset Schizophrenia 2019 Update. <b>2020</b> , 29, 157-170	9
633	Proposed symptom-based model of the origins of schizophrenia. <b>2020</b> , 134, 109428	
632	Effectiveness of integrated psychological therapy on cognitive function among Lebanese patients with schizophrenia: a pilot study. <b>2020</b> , 24, 43-52	2
631	ASP2905, a specific inhibitor of the potassium channel Kv12.2 encoded by the Kcnh3 gene, is psychoactive in mice. <b>2020</b> , 378, 112315	1
630	Global DNA hypomethylation and its correlation to the betaine level in peripheral blood of patients with schizophrenia. <b>2020</b> , 99, 109855	10
629	Population Pharmacokinetics of Paliperidone Palmitate (Once-Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia. <b>2020</b> , 9, 224-234	2
628	Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia?. <b>2020</b> , 23, 234-242	0
627	Clinical Effectiveness of Maintenance Electroconvulsive Therapy in Patients with Schizophrenia: A Retrospective Cohort Study. <b>2020</b> , 36, 42-46	4
626	Genomic treatment response prediction in schizophrenia. <b>2020</b> , 413-422	0
625	Socioeconomic deprivation and blood lipids in first-episode psychosis patients with minimal antipsychotic exposure: Implications for cardiovascular risk. <b>2020</b> , 216, 111-117	4
624	Self-Reported Sleep and Exercise Patterns in Patients with Schizophrenia: a Cross-Sectional Comparative Study. <b>2020</b> , 27, 366-377	4
623	Evaluation of social cognitive measures in an Asian schizophrenia sample. <b>2020</b> , 20, 100169	5
622	A powerful fine-mapping method for transcriptome-wide association studies. <b>2020</b> , 139, 199-213	12
621	Participatory development of a patient-clinician communication tool to enhance healthcare transitions for young people with 22q11.2. <b>2020</b> , 189, 761-769	1



620	Relationship of prolonged acoustic startle latency to diagnosis and biotype in the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) cohort. <b>2020</b> , 216, 357-366	5
619	Validation of the French Version of the Auditory Hallucination Rating Scale in a Sample of Hallucinating Patients with Schizophrenia: Validation de la version française de l'échelle d'évaluation des hallucinations auditives dans un échantillon de patients souffrant de schizophrénie et ayant des hallucinations. <b>2020</b> , 65, 237-244	4
618	Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain-related functional pathways. <b>2020</b> , 183, 140-151	
617	Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. <b>2020</b> , 45, 622-631	31
616	Sweat as a Source of Next-Generation Digital Biomarkers. <b>2019</b> , 3, 155-165	24
615	New Gambling Task Reveals an Atypical Relation Between Social Anxiety and Social Avoidance in Schizophrenia. <b>2020</b> , 1,	1
614	Assessment of Real-Life Outcomes in Schizophrenia Patients according to Compliance. <b>2020</b> , 2020, 5848601	2
613	Mortality and suicide in schizophrenia: 21-year follow-up in rural China. <b>2020</b> , 6, e121	4
612	The Potential Role of Traditional Medicine in the Management of Schizophrenia. <b>2020</b> , 22, 71	2
611	Wernicke Encephalopathy in schizophrenia: a systematic review. <b>2021</b> , 25, 233-237	5
610	The History of Writing Reflects the Effects of Education on Discourse Structure: Implications for Literacy, Orality, Psychosis and the Axial Age. <b>2020</b> , 21, 100142	1
609	Comparing psychotic experiences in low-and-middle-income-countries and high-income-countries with a focus on measurement invariance. <b>2020</b> , 1-8	3
608	Non-psychiatric hospitalization length-of-stay for patients with psychotic disorders: A mixed methods study. <b>2020</b> , 67, 1-9	4
607	Toxoplasma gondii: An Underestimated Threat?. <b>2020</b> , 36, 959-969	19
606	Sex-dependent association of mineralocorticoid receptor gene (NR3C2) DNA methylation and schizophrenia. <b>2020</b> , 292, 113318	6
605	Neuroethics at the interface of machine learning and schizophrenia. <b>2020</b> , 6, 18	3
604	The revised Psychosis Attachment Measure: Measuring disorganized attachment. <b>2020</b> , 59, 335-353	3
603	Characterising phospholipids and free fatty acids in patients with schizophrenia: A case-control study. <b>2021</b> , 22, 161-174	5

602	A new sex-specific underlying mechanism for female schizophrenia: accelerated skewed X chromosome inactivation. <b>2020</b> , 11, 39	3
601	Sex Differences in the Gut-Brain Axis: Implications for Mental Health. <b>2020</b> , 22, 83	15
600	Functional MRI in the effect of transcranial magnetic stimulation therapy for patients with schizophrenia: a meta-analysis protocol. <b>2020</b> , 10, e038557	3
599	Anterior Cingulate Cortex Glutamate Levels Are Related to Response to Initial Antipsychotic Treatment in Drug-Naive First-Episode Schizophrenia Patients. <b>2020</b> , 11, 553269	3
598	Neurobiology of maternal mental illness. <b>2020</b> , 171, 97-116	5
597	Epigenomic Dysregulation in Schizophrenia: In Search of Disease Etiology and Biomarkers. <b>2020</b> , 9,	20
596	Association of HLA-A, -B, -C, -DRB1 and -DQB1 alleles at amino acid level in individuals with schizophrenia: A study from South India. <b>2020</b> , 47, 501-511	1
595	Impact of Chronic Medical and Neuropsychiatric Illnesses on Quality of Life and Life Expectancy among Patients at the University of Port Harcourt Teaching Hospital (UPTH). <b>2020</b> ,	
594	Non Invasive Brain Stimulation in Psychiatry and Clinical Neurosciences. <b>2020</b> ,	1
593	The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review. <b>2020</b> , 118, 121-133	7
592	The role of norepinephrine in the pathophysiology of schizophrenia. <b>2020</b> , 118, 298-314	13
591	Early-Onset Schizophrenia in a paediatric population of French psychiatric and medico-social care centres: A cross sectional study. <b>2020</b> , 15, e0236241	4
590	Real-world effectiveness of admissions to a tertiary treatment-resistant psychosis service: 2-year mirror-image study. <b>2020</b> , 6, e82	4
589	The Y Chromosome: A Complex Locus for Genetic Analyses of Complex Human Traits. <b>2020</b> , 11,	1
588	Temporal trends in clozapine use at time of discharge among people with schizophrenia at two public psychiatric hospitals in Taiwan, 2006-2017. <b>2020</b> , 10, 17984	2
587	Brain-derived neurotrophic factor (BDNF) levels in first-episode schizophrenia and healthy controls: A comparative study. <b>2020</b> , 54, 102370	4
586	INTREPID II: protocol for a multistudy programme of research on untreated psychosis in India, Nigeria and Trinidad. <b>2020</b> , 10, e039004	5
585	The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. <b>2020</b> , 177, 868-872	113

584	Effects of haloperidol inhalation on MK-801- and memantine-induced locomotion in mice. <b>2020</b> , 15, 1808361	0
583	Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia?. <b>2020</b> , 33, 192-199	10
582	Analyzing acoustic and prosodic fluctuations in free speech to predict psychosis onset in high-risk youths. <b>2020</b> , 2020, 5575-5579	2
581	The prenatal challenge with lipopolysaccharide and polyinosinic:polycytidylic acid disrupts CX3CL1-CX3CR1 and CD200-CD200R signalling in the brains of male rat offspring: a link to schizophrenia-like behaviours. <b>2020</b> , 17, 247	12
580	Maintenance treatment with antipsychotic drugs for schizophrenia. <b>2020</b> , 8, CD008016	14
579	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). <b>2020</b> , 7, ofaa397	0
578	The Effect of Aerobic Exercise on Physical and Cognitive Outcomes in a Small Cohort of Outpatients with Schizophrenia. <b>2020</b> , 5, 161-174	8
577	Study protocol for the systematic review and meta-analyses of the association between schizophrenia and bone fragility. <b>2020</b> , 10, e041859	
576	Incidence and method of suicide mortality in patients with schizophrenia: a Nationwide Cohort Study. <b>2021</b> , 56, 1437-1446	3
575	Exploring the mRNA expression level of RELN in peripheral blood of schizophrenia patients before and after antipsychotic treatment. <b>2020</b> , 157, 43	1
574	Combined Metaheuristic Algorithm and Radiomics Strategy for the Analysis of Neuroanatomical Structures in Schizophrenia and Schizoaffective Disorders. <b>2020</b> , 42, 353-353	2
573	The clinical course of schizophrenia in women and men-a nation-wide cohort study. <b>2020</b> , 6, 12	36
572	Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia. <b>2020</b> , 60, 1355-1361	1
571	Experiences with legally mandated treatment in patients with schizophrenia: A systematic review of qualitative studies. <b>2020</b> , 63, e39	1
570	Chronic smoking and cognition in patients with schizophrenia: A meta-analysis. <b>2020</b> , 222, 113-121	6
569	Δ <sup>9</sup> -Tetrahydrocannabinol treatment during adolescence and alterations in the inhibitory networks of the adult prefrontal cortex in mice subjected to perinatal NMDA receptor antagonist injection and to postweaning social isolation. <b>2020</b> , 10, 177	5
568	Anthropological perspectives on the trajectory from institutionalisation to community care in Irish psychiatry. <b>2020</b> , 1-10	
567	A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States. <b>2020</b> , 15, e0234121	4

566	The impact of increasing general hospital admissions on Consultation-Liaison Psychiatry. <b>2020</b> , 28, 459-462	1
565	The impact of leprosy on the mental wellbeing of leprosy-affected persons and their family members - a systematic review. <b>2020</b> , 7, e15	8
564	Are Circadian Disturbances a Core Pathophysiological Component of Schizophrenia?. <b>2020</b> , 35, 325-339	15
563	DAILY time use, Physical Activity, quality of care and interpersonal relationships in patients with Schizophrenia spectrum disorders (DiAPASon): an Italian multicentre study. <b>2020</b> , 20, 287	0
562	Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data. <b>2020</b> , 11, 61	9
561	Binding of clozapine to the GABA receptor: clinical and structural insights. <b>2020</b> , 25, 1910-1919	24
560	Complement System in Brain Architecture and Neurodevelopmental Disorders. <b>2020</b> , 14, 23	28
559	Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs. <b>2019</b> , 10, 1669	9
558	Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment. <b>2020</b> , 286, 112890	16
557	The Cardiorespiratory Network in Healthy First-Degree Relatives of Schizophrenic Patients. <b>2020</b> , 14, 617	0
556	References. <b>2020</b> , 245-390	
555	Updating the Comparative Evidence on Second-Generation Antipsychotic Use With Schizophrenia. <b>2020</b> , 2, 76-87	0
554	Application of Support Vector Machine on fMRI Data as Biomarkers in Schizophrenia Diagnosis: A Systematic Review. <b>2020</b> , 11, 588	31
553	Cognitive-Behavioural Correlates of Dysbiosis: A Review. <b>2020</b> , 21,	6
552	Adolescent cannabinoid exposure interacts with other risk factors in schizophrenia: A review of the evidence from animal models. <b>2020</b> , 116, 202-220	6
551	Cost-effectiveness analysis of olanzapine and risperidone in schizophrenic patients in the Indian healthcare settings of Andhra Pradesh, India. <b>2020</b> , 11, 223-229	
550	The Role of Cytokines in Predicting the Efficacy of Acute Stage Treatment in Patients with Schizophrenia. <b>2020</b> , 16, 191-199	9
549	Restricted access carbon nanotube for microextraction by packed sorbent to determine antipsychotics in plasma samples by high-performance liquid chromatography-tandem mass spectrometry. <b>2020</b> , 412, 2465-2475	5

548	Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review. <b>2020</b> , 10,	24
547	ALDH4A1 expression levels are elevated in postmortem brains of patients with schizophrenia and are associated with genetic variants in enzymes related to proline metabolism. <b>2020</b> , 123, 119-127	5
546	Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring. <b>2020</b> , 10, 1219	1
545	Face pareidolia in schizophrenia. <b>2020</b> , 218, 138-145	6
544	Do the effects of cannabis on the hippocampus and striatum increase risk for psychosis?. <b>2020</b> , 112, 324-335	2
543	Circadian rhythm disruption and mental health. <b>2020</b> , 10, 28	160
542	Aberrantly High Levels of Somatic LINE-1 Expression and Retrotransposition in Human Neurological Disorders. <b>2019</b> , 10, 1244	21
541	From fighting animals to the biosocial mechanisms of the human mind: A comparison of Selten's social defeat and Mead's symbolic interaction. <b>2020</b> , 68, 1273-1289	3
540	Prostaglandins as the Agents That Modulate the Course of Brain Disorders. <b>2020</b> , 10, 1-13	10
539	Exogenous effects of oxytocin in five psychiatric disorders: a systematic review, meta-analyses and a personalized approach through the lens of the social salience hypothesis. <b>2020</b> , 114, 70-95	23
538	Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia. <b>2020</b> , 11, 379	17
537	Antipsychotic effects of sex hormones and atypical hemispheric asymmetries. <b>2020</b> , 127, 313-332	4
536	Overdispersed gene expression in schizophrenia. <b>2020</b> , 6, 9	8
535	Is that schizophrenia or frontotemporal dementia? Supporting clinicians in making the right diagnosis. <b>2020</b> , 120, 799-804	4
534	DNA Methylation Analysis of the NR3C1 Gene in Patients with Schizophrenia. <b>2020</b> , 70, 1177-1185	9
533	Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. <b>2020</b> , 20, 149	17
532	Meta-Analysis of Transcriptomic Data of Dorsolateral Prefrontal Cortex and of Peripheral Blood Mononuclear Cells Identifies Altered Pathways in Schizophrenia. <b>2020</b> , 11,	10
531	Disability digital divide: the use of the internet, smartphones, computers and tablets among people with disabilities in Sweden. <b>2021</b> , 20, 105-120	23

530	Action-Monitoring Alterations as Indicators of Predictive Deficits in Schizophrenia. <b>2021</b> , 13, 142-163	3
529	Serum zonulin and claudin-5 levels in patients with schizophrenia. <b>2021</b> , 271, 767-773	11
528	Treatment Capacity and Clinical Outcomes for Patients With Schizophrenia Who Were Treated With Electroconvulsive Therapy: A Retrospective Cohort Study. <b>2021</b> , 47, 424-432	1
527	Psychotic disorders, dopaminergic agents and EEG/MEG resting-state functional connectivity: A systematic review. <b>2021</b> , 120, 354-371	3
526	Meta-analysis of cognitive functioning in patients with psychotic disorders and obsessive-compulsive symptoms. <b>2021</b> , 271, 689-706	0
525	A systematic literature review of childhood externalizing psychopathology and later psychotic symptoms. <b>2021</b> , 28, 56-78	3
524	Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. <b>2021</b> , 91, 673-682	0
523	A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. <b>2021</b> , 105, 110134	2
522	Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. <b>2021</b> , 41, 1427-1473	26
521	Examining the dispensing patterns of antipsychotics in Australia from 2006 to 2018 - A pharmacoepidemiology study. <b>2021</b> , 17, 1159-1165	1
520	Low-Level Brain Somatic Mutations Are Implicated in Schizophrenia. <b>2021</b> , 90, 35-46	4
519	Relapse risk after in-ward electroconvulsive therapy for acute polymorphic psychotic disorder. <b>2021</b> , 75, 201-206	2
518	Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?. <b>2021</b> , 22, 635-646	3
517	The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts cognitive deficits induced by the D1/D2 dopaminergic receptor agonist apomorphine in rats. <b>2021</b> , 238, 227-237	3
516	Association between paternal age and risk of schizophrenia: a nationwide population-based study. <b>2021</b> , 38, 85-93	2
515	Disrupted circadian rhythms and mental health. <b>2021</b> , 179, 259-270	1
514	Diagnostic Performance of Increased Malondialdehyde Level and Oxidative Stress in Patients with Schizophrenia. <b>2021</b> , 58, 184-188	0
513	Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study. <b>2021</b> , 11, 20451253211000609	2

- 512 First-Episode & Early Psychosis in Transition-Age Youth. **2021**, 277-310
- 511 Prevalence of depression in schizophrenia and related disorders. **2021**, 155-166
- 510 Urgences psychiatriques en fonction des pathologies psychiatriques. **2021**, 35-66
- 509 Excess mortality in patients with schizophrenia spectrum disorders in Malaga (Spain): A cohort study. **2021**, 30, e11 2
- 508 Stem cell-based models and therapies: a key approach into schizophrenia treatment. **2021**, 22, 207-223 4
- 507 Childhood trauma and cardiometabolic risk in severe mental disorders: The mediating role of cognitive control. **2021**, 64, e24 2
- 506 Case studies of the treatment of schizophrenia patients. **2021**, 141-153
- 505 Effect of Transcranial Direct Current Stimulation on Hallucinations in Patients with Schizophrenia. **2021**, 491-499
- 504 The role of lumateperone in the treatment of schizophrenia. **2021**, 11, 20451253211034019 5
- 503 Schizophrenia during pregnancy. **2021**, 34, 238-244 4
- 502 Analysis Of Molecular Networks In The Cerebellum In Chronic Schizophrenia: Modulation By Early Postnatal Life Stressors In Murine Models.
- 501 Video games for people with schizophrenia. **2021**, 2, CD012844 2
- 500 Multifactorial barriers in the implementation of schizophrenia and psychosocial therapies guidelines: A quantitative study across different professions. **2021**, 228, 425-434 3
- 499 A Comprehensive Review of Computer-Aided Diagnosis of Major Mental and Neurological Disorders and Suicide: A Biostatistical Perspective on Data Mining. **2021**, 11, 3
- 498 Placental genomic risk scores and early neurodevelopmental outcomes. **2021**, 118, 8
- 497 Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: A targeted metabolomics study. **2021**, 75, 138-144 9
- 496 In situ-gelling starch nanoparticle (SNP)/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide. **2021**, 330, 738-752 12
- 495 An Observational Cohort of First Episode Psychosis in Iran: The Azeri Recent Onset Acute Phase Psychosis Survey (ARAS Cohort) Study Protocol. **2021**, 12, 627960 2

- 494 Clozapine metabolism is associated with Absolute Neutrophil Count in individuals with treatment-resistant schizophrenia.
- 493 Genetic architecture of schizophrenia: a review of major advancements. **2021**, 51, 2168-2177 19
- 492 Schizophrenic patients with type 2 diabetes: An 8-year population-based observational study. **2021**, 16, e0248407
- 491 Altered circadian rhythms in a mouse model of neurodevelopmental disorders based on prenatal maternal immune activation. **2021**, 93, 119-131 3
- 490 Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases. **2021**, 143, 487-494 0
- 489 Hippocampal regenerative medicine: neurogenic implications for addiction and mental disorders. **2021**, 53, 358-368 2
- 488 Causal associations between fatty acid measures and schizophrenia in a two-sample Mendelian randomization study.
- 487 Universal healthcare coverage for first episode of schizophrenia-spectrum disorders in Chile: analysis of the administrative database. **2021**, 1 1
- 486 Sparse deep neural networks on imaging genetics for schizophrenia case-control classification. **2021**, 42, 2556-2568 4
- 485 Language evolution: examining the link between cross-modality and aggression through the lens of disorders. **2021**, 376, 20200188 8
- 484 Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms. **2021**, 12, 631589 4
- 483 Awareness and attitudes towards common mental health problems of community members in Udupi Taluk, Karnataka: A mixed method study. **2021**, 10, 100679
- 482 Clozapine Metabolism is Associated With Absolute Neutrophil Count in Individuals With Treatment-Resistant Schizophrenia. **2021**, 12, 658734 5
- 481 Psychosis susceptibility Zinc Finger Protein 804A (ZNF804A) gene polymorphism in Schizophrenia patients treated with Olanzapine in North Indian population. **2021**, 1-9
- 480 Increasing Sample Diversity in Psychiatric Genetics by Introducing a new Cohort of Patients with Schizophrenia and Controls from Vietnam: Results from a Pilot Study.
- 479 Anesthesia Considerations for Cataract Surgery in Patients with Schizophrenia: A Narrative Review. **2021**, 11, e113750 4
- 478 Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. 2
- 477 Pharmacotherapy of schizophrenia: Mechanisms of antipsychotic accumulation, therapeutic action and failure. **2021**, 403, 113144 4



476	Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: A systematic review and meta-analysis. <b>2021</b> , 123, 203-214	17
475	Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia.	1
474	Schizophrenia Treatment Coverage Provided by the Public and Private Health Systems of Chile. <b>2021</b> , 72, 478-481	0
473	Schizophrenia hospitalization in the US 2005-2014: Examination of trends in demographics, length of stay, and cost. <b>2021</b> , 100, e25206	1
472	Forensic psychiatric evaluation of 187 homicidal assailants with and without a schizophrenia spectrum disorder: Clinical, criminological and behavioral characteristics. <b>2021</b> , 39, 190-204	2
471	Genome-wide association study of antipsychotic-induced sinus bradycardia in Chinese schizophrenia patients. <b>2021</b> , 16, e0249997	1
470	Ultra-rare, rare, and common genetic variant analysis converge to implicate negative selection and neuronal processes in the aetiology of schizophrenia.	
469	Collaborative Care in the Identification and Management of Psychosis in Adolescents and Young Adults. <b>2021</b> , 147,	1
468	Early Environmental Upheaval and the Risk for Schizophrenia. <b>2021</b> , 17, 285-311	11
467	An Observational Study of, EEG Abnormalities and Clinical Outcome in Schizophrenia, Conducted in Government Hospital for Mental Care in Visakhapatnam. <b>2021</b> , 8, 1820-1825	
466	Evoluci3n en el diagn3stico de la esquizofrenia en el departamento de Caldas, Colombia. 2010-2015. <b>2021</b> , 69, e73159	
465	Serum interleukin-6 in schizophrenia: A system review and meta-analysis. <b>2021</b> , 141, 155441	12
464	Genome-wide analyses of smoking behaviors in schizophrenia: Findings from the Psychiatric Genomics Consortium. <b>2021</b> , 137, 215-224	3
463	Evidence for Reduced Long-Term Potentiation-Like Visual Cortical Plasticity in Schizophrenia and Bipolar Disorder. <b>2021</b> , 47, 1751-1760	0
462	Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. <b>2021</b> , 11, 9992	9
461	Akt-mTOR hypoactivity in bipolar disorder gives rise to cognitive impairments associated with altered neuronal structure and function. <b>2021</b> , 109, 1479-1496.e6	6
460	Prenatal infection and schizophrenia: A decade of further progress. <b>2021</b> ,	6
459	Transcriptome analysis reveals disparate expression of inflammation-related miRNAs and their gene targets in iPSC-astrocytes from people with schizophrenia. <b>2021</b> , 94, 235-244	3

458	Analysis of whole exome sequencing in severe mental illness hints at selection of brain development and immune related genes.	
457	White Matter Integrity of the Corpus Callosum and Psychopathological Dimensions in Deficit and Non-Deficit Schizophrenia Patients. <b>2021</b> , 10,	4
456	Genetic investigations of 100 inherited cardiac disease-related genes in deceased individuals with schizophrenia. <b>2021</b> , 135, 1395-1405	0
455	Toxoplasma gondii infection by serological and molecular methods in schizophrenia patients with and without suicide attempts: An age-sex-matched case-control study. <b>2021</b> , 75, e14449	1
454	Clinical Staging in Schizophrenia Spectrum Disorders.	1
453	Schizophrenia Plays a Negative Role in the Pathological Development of Myocardial Infarction at Multiple Biological Levels. <b>2021</b> , 12, 607690	0
452	Discontinuity of psychiatric care for patients with schizophrenia, relation to previous psychiatric care and practice variation between providers: a retrospective longitudinal cohort study. <b>2021</b> , 21, 319	0
451	Description the Importance of Developing a Self-Reliance Instrument for Schizophrenic Patients in the Hospital Setting. <b>2021</b> , 9, 14-18	0
450	Rates of Inpatient and Emergency Room Use Before and After Discharge Among Medicaid Enrollees in OnTrackNY. <b>2021</b> , 72, 1328-1331	1
449	Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction. <b>2021</b> ,	5
448	Schizophrenia, the gut microbiota, and new opportunities from optogenetic manipulations of the gut-brain axis. <b>2021</b> , 17, 7	6
447	Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia. <b>2021</b> , 9, 24932	1
446	Philosophy of Psychiatry. <b>2021</b> ,	3
445	Being Born in Winter-Spring and at Around the Time of an Influenza Pandemic Are Risk Factors for the Development of Schizophrenia: The Apna Study in Navarre, Spain. <b>2021</b> , 10,	0
444	Glutathione Deficiency during Early Postnatal Development Causes Schizophrenia-Like Symptoms and a Reduction in BDNF Levels in the Cortex and Hippocampus of Adult Sprague-Dawley Rats. <b>2021</b> , 22,	6
443	Environmental Risk Factors for Schizophrenia and Bipolar Disorder and Their Relationship to Genetic Risk: Current Knowledge and Future Directions. <b>2021</b> , 12, 686666	13
442	Serum tumor necrosis factor-like weak inducer of apoptosis levels are elevated in schizophrenia. <b>2021</b> , 43, 242-246	2
441	Risk and protective factors of relapse in patients with first-episode schizophrenia from perspectives of health professionals: a qualitative study in northeastern Thailand. 10, 499	0

440 Schizophrenia. **2021**, 311-334

439 Disturbances in White Matter Integrity in the Ultra-High-Risk Psychosis State-A Systematic Review. **2021**, 10, 4

438 A Review on the Expression Pattern of Non-coding RNAs in Patients With Schizophrenia: With a Special Focus on Peripheral Blood as a Source of Expression Analysis. **2021**, 12, 640463 6

437 Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile. **2021**, 17, 2141-2150 2

436 Common and Distinct Alterations of Cognitive Function and Brain Structure in Schizophrenia and Major Depressive Disorder: A Pilot Study. **2021**, 12, 705998 1

435 Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review. **2021**, 13, 279-296 0

434 Neanderthal-derived genetic variation in living humans relates to schizophrenia diagnosis, to psychotic symptom severity, and to dopamine synthesis. **2021**, 186, 329-338 1

433 Transcriptomic Data Analysis Reveals a Down-Expression of in Schizophrenia Hippocampus. **2021**, 11, 1

432 Utilization of Health Care Services by Patients With Cluster B Personality Disorders or Schizophrenia. **2021**, 72, 1392-1399 0

431 Psychosocial interventions for people with a first episode psychosis: between tradition and innovation. **2021**, 34, 460-466 0

430 Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. **2021**, 12, 661174 3

429 Increasing sample diversity in psychiatric genetics - Introducing a new cohort of patients with schizophrenia and controls from Vietnam - Results from a pilot study. **2021**, 1-9 0

428 Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients. **2021**, 14, 1015-1025 0

427 Transcription factors in neurodevelopmental and associated psychiatric disorders: A potential convergence for genetic and environmental risk factors. **2021**, 81, 545-578 4

426 Incidence rates and employment trends in schizophrenia spectrum disorders, bipolar affective disorders and recurrent depression in the years 2000-2013: a Danish nationwide register-based study. **2021**, 1-8 1

425 Sch-net: a deep learning architecture for automatic detection of schizophrenia. **2021**, 20, 75 0

424 Binding of SEP-363856 within TAAR1 and the 5HT receptor: implications for the design of novel antipsychotic drugs. **2021**, 3

423 Polygenic risk scores for schizophrenia are associated with oculomotor endophenotypes. **2021**, 1-9 0

422	Toxoplasma infection alters dopamine-sensitive behaviors and host gene expression patterns associated with neuropsychiatric disease.	
421	Self-consciousness impairments in schizophrenia with and without first rank symptoms using the moving rubber hand illusion. <b>2021</b> , 93, 103154	0
420	The Role of Cytokines in the Pathogenesis of Schizophrenia. <b>2021</b> , 10,	10
419	Analysis of Molecular Networks in the Cerebellum in Chronic Schizophrenia: Modulation by Early Postnatal Life Stressors in Murine Models. <b>2021</b> , 22,	2
418	Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review. <b>2021</b> , 12, 699748	1
417	Association of the NOTCH4 gene polymorphism with schizophrenia in the Indian population. <b>2021</b> , 29, 100903	
416	Transcriptomics Analysis Reveals Shared Pathways in Peripheral Blood Mononuclear Cells and Brain Tissues of Patients With Schizophrenia. <b>2021</b> , 12, 716722	1
415	Sex Differences in Dopamine Receptors and Relevance to Neuropsychiatric Disorders. <b>2021</b> , 11,	5
414	Prolonged grief disorder, posttraumatic stress disorder, and depression following traffic accidents among bereaved Balinese family members: Prevalence, latent classes and cultural correlates. <b>2021</b> , 292, 773-781	3
413	Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies. <b>2021</b> , 17, 1211-1221	3
412	Validity and reliability of the Vigour Assessment Scale in avolitional schizophrenia outpatients. <b>2021</b> , 235, 36-43	0
411	Doxycycline exposure during adolescence and future risk of non-affective psychosis and bipolar disorder: a total population cohort study. <b>2021</b> , 11, 468	0
410	Safety profile of clozapine: Analysis using national registry data in Japan. <b>2021</b> , 141, 116-123	0
409	Association between TLR2 polymorphisms (- 196-174 Ins/Del, R677W, R753Q, and P631H) and schizophrenia in a Tunisian population. <b>2021</b> , 69, 541-552	1
408	Assessing the physical healthcare gap among patients with severe mental illness: large real-world investigation from Italy. <b>2021</b> , 7,	78
407	The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity. <b>2021</b> ,	3
406	Review: Influence of the CYP450 Genetic Variation on the Treatment of Psychotic Disorders. <b>2021</b> , 10,	1
405	The association between chronotype and sleep quality, and cardiometabolic markers in patients with schizophrenia. <b>2021</b> , 1-12	1

404	Neuroepigenetics of psychiatric disorders: Focus on lncRNA. <b>2021</b> , 149, 105140	3
403	Positive allosteric modulators (PAMs) of the group II metabotropic glutamate receptors: Design, synthesis, and evaluation as ex-vivo tool compounds. <b>2021</b> , 50, 128342	0
402	The association of medical resource utilization with physical morbidity and premature mortality among patients with schizophrenia: An historical prospective population cohort study. <b>2021</b> , 237, 62-68	0
401	Target selection for deep brain stimulation in treatment resistant schizophrenia. <b>2022</b> , 112, 110436	3
400	Transition-Age Youth with Autism Spectrum Disorder. <b>2021</b> , 211-235	0
399	Development of salutogenic coping skills: experiences with daily challenges among young adults suffering from serious mental illness. <b>2021</b> , 16, 1879369	1
398	Psychotogenesis. <b>2021</b> , 13-31	
397	Astroglial cells as neuroendocrine targets in forebrain development: Implications for sex differences in psychiatric disease. <b>2021</b> , 60, 100897	4
396	Antipsychotic medication adherence and preventive diabetes screening in Medicaid enrollees with serious mental illness: an analysis of real-world administrative data. <b>2021</b> , 21, 69	1
395	User-held personalised information for routine care of people with severe mental illness. <b>2013</b> , CD001711	12
394	Yoga as part of a package of care versus standard care for schizophrenia. <b>2017</b> , 9, CD012145	9
393	Mental Illness, Women, Mothers and their Children. 483-515	8
392	Co-Regulation and Epigenetic Dysregulation in Schizophrenia and Bipolar Disorder. <b>2012</b> , 281-347	3
391	Schizophrenia in Women. <b>2020</b> , 49-58	1
390	Behavioural Interventions for Weight Management Among Patients with Schizophrenia. <b>2017</b> , 257-273	1
389	Schizophrenia. <b>2017</b> , 267-290	7
388	Treatment-Refractory Schizophrenia: Definition and Assessment. <b>2014</b> , 1-19	5
387	Course of Schizophrenia: What Has Been Learned from Longitudinal Studies?. <b>2011</b> , 281-300	1

386	Measuring Anhedonia in Schizophrenia-Spectrum Disorders: A Selective Update. <b>2014</b> , 19-54	5
385	Association of HSPA1B genotypes with psychopathology and neurocognition in patients with the first episode of psychosis: a longitudinal 18-month follow-up study. <b>2020</b> , 20, 638-646	3
384	Inhibition of mechanistic target of rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta. <b>2020</b> , 134, 3123-3136	5
383	Cat-dependent diseases cost Australia AU\$6 billion per year through impacts on human health and livestock production. <b>2020</b> , 47, 731	9
382	The Burden of Mental Disorders. <b>2012</b> , 2-30	3
381	The Relationship of Adult Mental Disorders to Socioeconomic Status, Race/Ethnicity, Marital Status, and Urbanicity of Residence. <b>2012</b> , 151-197	5
380	Gene Expression Elucidates Functional Impact of Polygenic Risk for Schizophrenia.	3
379	Association of polygenic risk for major psychiatric illness with subcortical volumes and white matter integrity in UK Biobank.	1
378	Deconvolution of Transcriptional Networks Identifies TCF4 as a Master Regulator in Schizophrenia.	1
377	Mitochondrial DNA SNPs associated with Schizophrenia exhibit Highly Variable Inter-allelic Haplogroup Affiliation and Nuclear Genogeographic Affinity: Bi-Genomic Linkage Disequilibrium raises Major Concerns for Link to Disease.	2
376	Exome sequencing identifies rare coding variants in 10 genes which confer substantial risk for schizophrenia.	39
375	Brain-Specific Deletion of GIT1 Impairs Cognition and Alters Phosphorylation of Synaptic Protein Networks Implicated in Schizophrenia Susceptibility.	2
374	How to control for confounds in decoding analyses of neuroimaging data.	3
373	Overdispersed gene expression characterizes schizophrenic brains.	2
372	Dynamic landscape and genetic regulation of RNA editing in schizophrenia.	1
371	Clozapine-induced stercoral colitis: a surgical perspective. <b>2019</b> , 12,	3
370	Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction). <b>2019</b> , 9, e030912	15
369	Metacognitive training for schizophrenia: a systematic review. <b>2015</b> , 27, 149-57	17

368	Social Functioning in Schizophrenia Clinical Correlations. <b>2018</b> , 44, 151-156	2
367	Association between schizophrenia and urinary calculi: a population-based case-control study. <b>2013</b> , 8, e56942	1
366	The roles of reward, default, and executive control networks in set-shifting impairments in schizophrenia. <b>2013</b> , 8, e57257	78
365	Recording of severe mental illness in United Kingdom primary care, 2000-2010. <b>2013</b> , 8, e82365	55
364	Network-Based Analysis of Schizophrenia Genome-Wide Association Data to Detect the Joint Functional Association Signals. <b>2015</b> , 10, e0133404	24
363	Reported family burden of schizophrenia patients in rural China. <b>2017</b> , 12, e0179425	44
362	Mixed methods inquiry into traditional healers' treatment of mental, neurological and substance abuse disorders in rural South Africa. <b>2017</b> , 12, e0188433	21
361	The impact of a short-term cohousing initiative among schizophrenia patients, high school students, and their social context: A qualitative case study. <b>2018</b> , 13, e0190895	2
360	CalPen (Calculator of Penetrance), a web-based tool to estimate penetrance in complex genetic disorders. <b>2020</b> , 15, e0228156	1
359	The Stones That the Builders Rejected: The Scapegoat Mechanism and Evolutionary Psychiatry. <b>2020</b> , 27, 59	1
358	Low levels of muscarinic M1 receptor-positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia. <b>2018</b> , 43, 338-346	18
357	Abnormalities of intrinsic regional brain activity in first-episode and chronic schizophrenia: a meta-analysis of resting-state functional MRI. <b>2020</b> , 45, 55-68	23
356	Modeling of the Bipolar Disorder and Schizophrenia Using Patient-Derived Induced Pluripotent Stem Cells with Copy Number Variations of 5 and. <b>2019</b> , 6,	26
355	[The activity of enzymes of glutathione metabolism in blood cells of patients with a high risk of manifestation of endogenous psychoses and patients with the first psychotic episode]. <b>2019</b> , 119, 47-54	6
354	Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia. <b>2019</b> , 20, 1652-1669	8
353	Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. <b>2017</b> , 15, 1192-1207	31
352	Mobile Texting and Lay Health Supporters to Improve Schizophrenia Care in a Resource-Poor Community in Rural China (LEAN Trial): Randomized Controlled Trial Extended Implementation. <b>2020</b> , 22, e22631	4
351	New Tools for New Research in Psychiatry: A Scalable and Customizable Platform to Empower Data Driven Smartphone Research. <b>2016</b> , 3, e16	245

350	Decreased IL-1ra and NCAM-1/CD56 Serum Levels in Unmedicated Patients with Schizophrenia Before and After Antipsychotic Treatment. <b>2018</b> , 15, 727-732	3
349	The epidemiology of schizophrenia: replacing dogma with knowledge. <b>2010</b> , 12, 305-15	69
348	Use of the epigenetic toolbox?to contextualize common variants associated with schizophrenia risk?. <b>2019</b> , 21, 407-416	2
347	Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review. <b>2018</b> ,	3
346	Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. <b>2013</b> , 5, 2	28
345	Genetic variation in the 3'-untranslated region of influences schizophrenia susceptibility. <b>2017</b> , 13, 1101-1108	2
344	Early Intervention for Psychosis: The Recovery After an Initial Schizophrenia Episode Project. <b>2015</b> , 45, 548-553	12
343	Retrospective analysis of treatment effectiveness among patients in Mianyang Municipality enrolled in the national community management program for schizophrenia. <b>2012</b> , 24, 131-9	10
342	Executive function in patients with schizophrenia based on socio-occupational impairment: A cross-sectional study. <b>2018</b> , 27, 181-189	3
341	Schizophrenia, cancer and obstetric complications in an evolutionary perspective-an empirically based hypothesis. <b>2011</b> , 8, 77-88	12
340	Genetic aspects in schizophrenia. Receptor theories. Metabolic theories. <b>2020</b> , 61, 25-32	5
339	Prevalence of Metabolic Syndrome in Patients with Schizophrenia Referred to Farabi Hospital, Kermanshah, Iran. <b>2016</b> , 31, 270-5	9
338	Facial emotion perception in schizophrenia: Does sex matter?. <b>2016</b> , 6, 257-68	9
337	Women who suffer from schizophrenia: Critical issues. <b>2018</b> , 8, 125-136	18
336	The role of estrogen in the treatment of men with schizophrenia. <b>2013</b> , 11, 129-36	39
335	Expression of schizophrenia biomarkers in extraocular muscles from patients with strabismus: an explanation for the link between exotropia and schizophrenia?. <b>2017</b> , 5, e4214	5
334	Korean Sibling Caregivers of Individuals Diagnosed with Schizophrenia. <b>2017</b> , 2, 97-102	4
333	Economic burden to commercial payers of young adults with schizophrenia in Colorado. <b>2021</b> , 24, 1194-1203	



- 332 Humour-based interventions for people with schizophrenia. **2021**, 10, CD013367 1
- 331 Disorganization of Oscillatory Activity in Animal Models of Schizophrenia. **2021**, 15, 741767 0
- 330 Novel microRNAs targeting NMDA receptor subunits in animal models of schizophrenia. 0
- 329 Association of the First Antipsychotic Treatment Duration With the Re-Initiation of Treatment in Schizophrenia: A National Health Insurance Data-Based Study. **2021**, 24, 60-67
- 328 Analysis of whole exome sequencing in severe mental illness hints at selection of brain development and immune related genes. **2021**, 11, 21088 0
- 327 Thirteen-year follow-up of long-term treated psychotic disorder: personality aspects. **2021**, 1-8
- 326 Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. **2021**, 35, 1189-1205 3
- 325 The influence of childhood trauma on aggression and violent behavior in first episode psychosis: A critical review. **2021**, 61, 101677 0
- 324 Managing schizophrenia: the role of primary care. **2010**, 2010,
- 323 Effet de la complexité de la prescription et du suivi symptomatique sur l'observance du traitement chez les patients tunisiens atteints de schizophrénie. **2010**, 49, 204-212
- 322 Epidemiology. **2012**, 23-34
- 321 Mortalin in Neurological Diseases. **2012**, 139-158
- 320 The Population Dynamics of Mental Disorders. **2012**, 124-150 1
- 319 Suicidio e patologia psichiatrica. **2013**, 59-82
- 318 Psychosis and Gender: Everything You Always Wanted to Know About Sex (and Gender) in Psychosis but Were Afraid to Ask. **2015**, 361-387
- 317 Schizophrenien und andere psychotische Störungen. **2015**, 349-412
- 316 Les mères schizophréniques et leurs enfants. **2015**, 287-307
- 315 Metacognition in Relation to Cognitive and Social Functioning in Schizophrenia. **2015**, 6, 24-33

- 314 Severe Psychopathology. **2016**, 301-314
- 313 Early-Onset Psychosis and Child and Adolescent Schizophrenia. **2016**, 4, 1-3 2
- 312 Schizofrenia ad esordio in et  evolutiva: aspetti clinici e interventi possibili. **2016**, 25-41
- 311 Schizophrenie. **2017**, 7-37
- 310 Placental gene expression mediates the interaction between obstetrical history and genetic risk for schizophrenia. 0
- 309 Serious Mental Disorders in Older Adults. 241-280 0
- 308 Estradiol and luteinizing hormone reverse memory loss in phencyclidine model of schizophrenia: Evidence for hippocampal GABA action. 1
- 307 Psychotropic drugs in pregnancy - do they reduce or increase the risks for the fetus? Part One: antidepressants, antipsychotics. **2017**, 18, 282-286 1
- 306 Pharmacoeconomic aspects of schizophrenia. **2018**, 10, 37-41
- 305 8 Syndromen. **2018**, 289-477
- 304 Caract risation des premiers  isodes de schizophr nie   partir de bases de donn es administratives de sant  jumel es. **2018**, 43, 83
- 303 Psychosis: Schizophrenia and Related Disorders. **2018**, 335-372
- 302 Psychosis and Suicide. **2018**, 53-69
- 301 Schizophrenia.
- 300 Family Inclusive Therapeutic Interventions. **2019**, 169-185
- 299 Multi-scale analysis of schizophrenia risk loci: Integrating centenarian genomes and spatio-temporal expression profiles suggests the need for adjunctive therapeutic interventions for neuropsychiatric disorders. 0
- 298 Brain-based ranking of cognitive domains to predict schizophrenia.
- 297  zofreni hastalarında ortalama trombosit hacminin de erlendirilmesi. 102-107

- 296 Genetic Evidence for the Association between Schizophrenia and Breast Cancer. **2018**, 3, 6
- 295 Psychiatric Comorbidity of Cannabis Use Disorder. **2019**, 113-125 2
- 294 Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Neurocognitive Profile. **2018**, 48, 557-560
- 293 Hubungan Faktor Trauma Masa Lalu dengan Status Mental Beresiko Gangguan Psikosis Pada Remaja Akhir di DKI Jakarta. **2018**, 3, 73
- 292 Single-nucleotide Polymorphism of CTLA-4 (rs5742909) in Correlation with Schizophrenia Risk Factor. **2019**, 11, S605-S610 0
- 291 Special Populations: Gender, Race, and Incarcerated Individuals. **2019**, 57-66
- 290 Encyclopedia of Personality and Individual Differences. **2019**, 1-6
- 289 Psychosis. **2019**, 869-893
- 288 Schizophrenien und andere psychotische Störungen. **2019**, 301-362.e7
- 287 The Effect of Cannabidiol on Psychosis-like Behaviour Induced by Methamphetamine and MK-801 in Mice: A Negative Report. **2019**,
- 286 Allgemeine Grundlagen (Modul 1). **2019**, 1-12
- 285 Improving Our Science in Research with Sex- and Gender-Based Analysis. **2019**, 139-168
- 284 Encyclopedia of Personality and Individual Differences. **2019**, 1-6
- 283 Everything You Always Wanted to Know About Sex (and Gender) in Psychosis But Were Afraid to Ask: A Narrative Review. **2019**, 453-479 0
- 282 Behandlung unter besonderen Bedingungen (Modul 4c). **2019**, 181-254
- 281 Schizophrenia. **2019**, 261-292
- 280 [Regional differences in the incidence of affective disorders]. **2019**, 119, 10-16 2
- 279 First-Episode Psychosis from the Perspective of Family Members. **2019**, 57, 34-42

278 The exhaustive genomic scan approach, with an application to rare-variant association analysis.

277 Epigenetic age is accelerated in schizophrenia with age- and sex-specific effects and associated with polygenic disease risk. 2

276 Einleitung. **2019**, 9-12

275 Geographische Breite, latitude. **2019**, 17-22

274 Randomized Controlled Trials and the Efficacy of Psychotropic Medications. **2020**, 1-56

273 Using polygenic risk score approaches to investigate the common-variant genetic architecture of schizophrenia. **2019**, 8-11

272 İzofreni ve İltihar; Bir G zden Ge rme. **2019**, 3, 135-146

271 Psychotische Erkrankungen (Schizophrenie) **2020**, 275-296

270 Encyclopedia of Personality and Individual Differences. **2020**, 4575-4580 1

269 Effects of country of origin and wave of immigration on prevalence of schizophrenia among first and second-generation immigrants: A 30-year retrospective study. **2020**, 0

268 G protein gene variants in schizophrenia. **2020**, 47, 31-34

267 Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics. **2020**, 13, 1170-1177 2

266 Sparse Deep Neural Networks on Imaging Genetics for Schizophrenia Case-Control Classification.

265 Evidence for reduced long-term potentiation-like visual cortical plasticity in schizophrenia and bipolar disorder.

264 Mobile Texting and Lay Health Supporters to Improve Schizophrenia Care in a Resource-Poor Community in Rural China (LEAN Trial): Randomized Controlled Trial Extended Implementation (Preprint).

263 Serum galectin-3 levels are decreased in schizophrenia. **2020**, 42, 398-402

262 Transcriptome Analysis of Human Induced Excitatory Neurons Supports a Strong Effect of Clozapine on Cholesterol Biosynthesis.

261 A human iPSC-astroglia neurodevelopmental model reveals divergent transcriptomic patterns in schizophrenia. **2021**, 11, 554 4

260	Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study. <b>2021</b> , 8, 1062-1070	2
259	A Novel Genotyping Method for Detection of the Muscarinic Receptor Gene rs2067477 Polymorphism and Its Genotype/Allele Frequencies in a Turkish Population. <b>2020</b> , 17, 653-658	
258	MicroRNA profiling of the pig periaqueductal grey (PAG) region reveals candidates potentially related to sex-dependent differences. <b>2020</b> , 11, 67	
257	Psychotische Störungen und Schizophrenie. <b>2020</b> , 947-1003	
256	Genetics and Neuroimaging in Schizophrenia. <b>2020</b> , 319-342	0
255	Transcranial Direct Current Stimulation for the Treatment of Hallucinations in Patients with Schizophrenia. <b>2020</b> , 239-248	
254	8.8 Psychosesyndroom. <b>2018</b> , 375-385	
253	Antipsychotic Medication in Schizophrenic Patients is Associated with Higher Risks of Developing Bone Fractures and Refractures. <b>2020</b> , 18, 562-570	
252	Animal Models for Brain Research. <b>2021</b> , 3-55	
251	A human iPSC-astroglia neurodevelopmental model reveals divergent transcriptomic patterns in schizophrenia.	
250	The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. <b>2020</b> , 18, 493-497	5
249	Schizophrenia. <b>2012</b> , 2012,	5
248	Does consanguinity increase the risk of schizophrenia? Study based on primary health care centre visits. <b>2012</b> , 9, 241-8	11
247	Using focus groups to design a psychoeducation program for patients with schizophrenia and their family members. <b>2014</b> , 7, 177-85	3
246	CB1 cannabinoid receptors are involved in neuroleptic-induced enhancement of brain neurotensin. <b>2014</b> , 17, 181-8	3
245	Identifying Some Risk Factors of Time to Relapses in Schizophrenic Patients using Bayesian Approach with Event-Dependent Frailty Model. <b>2015</b> , 10, 123-7	2
244	Brexpirazole: A New Treatment Option for Schizophrenia. <b>2016</b> , 13, 26-9	5
243	Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia. <b>2016</b> , 9, 399-410	6

242	Catechol-O-Methyltransferase (COMT) Gene (Val158Met) and Brain-Derived Neurotrophic Factor (BDNF) (Val66Met) Genes Polymorphism in Schizophrenia: A Case-Control Study. <b>2017</b> , 12, 265-270	4
241	Correlated expression analysis of genes implicated in schizophrenia: identification of putative disease-related pathways. <b>2017</b> , 3, 224-232	3
240	Asenapine Transdermal Patch for the Management of Schizophrenia. <b>2020</b> , 50, 60-82	3
239	QSAR modeling and docking analysis of D2 receptor with known olanzapine derivatives. <b>2020</b> , 16, 666-671	
238	Corrigendum: Base Rates, Blindness, and Schizophrenia. <b>2021</b> , 12, 732333	
237	Long term course and outcome of first episode schizophrenia: a 27-to-31-year follow-up. <b>2021</b> , 1	
236	Breast cancer in schizophrenia could be interleukin-33-mediated. <b>2021</b> , 11, 1065-1074	1
235	Quality of life and self-stigma of schizophrenia patient's caregiver tool: Development and validation using classical test theory and Rasch analysis.. <b>2021</b> , 27, 1656	
234	Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews. <b>2021</b> , 1	1
233	Efficacy and safety of add-on sodium benzoate, a D-amino acid oxidase inhibitor, in treatment of schizophrenia: A systematic review and meta-analysis. <b>2021</b> , 68, 102947	1
232	Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier.. <b>2021</b> , 13,	4
231	Altered Peripheral Immune Profiles in First-Episode, Drug-Free Patients With Schizophrenia: Response to Antipsychotic Medications.. <b>2021</b> , 8, 757655	1
230	Point-in-time survey of healthcare resource utilization, employment, quality of life and caregiver status by disease severity in patients with schizophrenia in the US. <b>2021</b> , 1-10	1
229	Epilepsy in patients with schizophrenia: Pathophysiology and basic treatments.. <b>2022</b> , 127, 108520	0
228	Healthcare resource utilization and quality of life by cognitive impairment in patients with schizophrenia.. <b>2022</b> , 28, 100233	2
227	Psychosis in Children and Youth: Focus on Early-Onset Schizophrenia. <b>2013</b> , 34, 296-306	2
226	Chapitre 1. Schizophrenie(s): cliniques. <b>2015</b> , 5-18	
225	QSAR modeling and docking analysis of D2 receptor with known olanzapine derivatives. <b>2020</b> , 16, 666-671	

224	A Review on Schizophrenia Diagnosis and Management Approach. <b>2021</b> , 10, 72-74	
223	Clinical experience with newer antipsychotics. <b>2021</b> , 22, 143-148	
222	Understanding the Effects of Antipsychotics on Appetite Control.. <b>2021</b> , 8, 815456	1
221	The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population.. <b>2021</b> , 1-26	1
220	Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia.. <b>2022</b> , 13, 51	0
219	D-Amino Acids as a Biomarker in Schizophrenia.. <b>2022</b> , 10,	1
218	Survey on Structural Neuro imaging for the Identification of brain Abnormalities in Schizophrenia.. <b>2022</b> ,	0
217	From the Blood-Brain Barrier to Childhood Development: A Case of Acute-Onset Psychosis and Cognitive Impairment Attributed to Systemic Lupus Erythematosus in an Adolescent Female.. <b>2022</b> , 30, 71-82	1
216	Clinical experience with paliperidone palmitate in a specialty hospital in the Philippines: A short report.	
215	Schizophrenia.. <b>2022</b> , 399, 473-486	11
214	Duration of untreated psychosis and pathways to care in Suriname: a qualitative study among patients, relatives and general practitioners.. <b>2022</b> , 12, e050731	
213	"MAP Bayesian modeling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients".. <b>2022</b> ,	
212	Role of deep brain stimulation in management of psychiatric disorders.. <b>2022</b> , 270, 61-96	
211	Male sex bias in early and late onset neurodevelopmental disorders: shared aspects and differences in autism spectrum disorder, attention deficit/hyperactivity disorder, and schizophrenia.. <b>2022</b> , 135, 104577	2
210	Disease-Related Risk Factors for Caregiver Burden among Family Caregivers of Persons with Schizophrenia: A Systematic Review and Meta-Analysis.. <b>2022</b> , 19,	2
209	Effectiveness of Double-Hit Model (Post-Weaning Social Isolation and NMDA Receptor Antagonist) in the Development of Schizophrenic like Symptoms on Rodents: A Protocol for a Systematic Review. <b>2022</b> , 3, 111-118	
208	Verbal manifestations of metacognitive and social cognitive operations in patients with schizophrenia who received metacognitive training. 1	
207	Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia.. <b>2021</b> , 21, 620	2

206	A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia.. <b>2021</b> , 46, E675-E701	2
205	Meta-analysis of genomic variants and gene expression data in schizophrenia suggests the potential need for adjunctive therapeutic interventions for neuropsychiatric disorders. <b>2019</b> , 98,	2
204	Dual Hit Mouse Model to Examine the Long-Term Effects of Maternal Immune Activation and Post-Weaning Social Isolation on Schizophrenia Endophenotypes.	
203	Sex Differences in Psychosis: Focus on Animal Models.. <b>2022</b> , 1	0
202	Users' Psychopathologies: Impact on Cybercrime Vulnerabilities and Cybersecurity Behavior. <b>2022</b> , 93-134	0
201	A CROSS-SECTIONAL STUDY OF THE QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA.. <b>2022</b> , 104-108	
200	OCT and OCT Angiography Offer New Insights and Opportunities in Schizophrenia Research and Treatment.. <b>2022</b> , 4, 836851	0
199	Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder.. <b>2022</b> , 22, 114	0
198	The Impact of Poor Nonverbal Social Perception on Functional Capacity in Schizophrenia.. <b>2022</b> , 13, 804093	0
197	Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a New Genotype.. <b>2021</b> , 12, 830608	1
196	Anodal transcranial Direct Current Stimulation over the cerebellum and primary motor cortex improves tardive dyskinesia: A pilot study.. <b>2022</b> , 15, 488-490	0
195	Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology.. <b>2022</b> , 179, 189-203	1
194	A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia.. <b>2022</b> ,	0
193	Comparison of Machine Learning Algorithms in the Prediction of Hospitalized Patients with Schizophrenia.. <b>2022</b> , 22,	0
192	CGP17Pat: Automated Schizophrenia Detection Based on a Cyclic Group of Prime Order Patterns Using EEG Signals.. <b>2022</b> , 10,	1
191	Pattern of predictive features of continued cannabis use in patients with recent-onset psychosis and clinical high-risk for psychosis.. <b>2022</b> , 8, 19	
190	Impact of COMT, PRODH and DISC1 Genetic Variants on Cognitive Performance of Patients with Schizophrenia.. <b>2022</b> ,	
189	Family caregiving and chronic illness management in schizophrenia: positive and negative aspects of caregiving.. <b>2022</b> , 10, 83	2



188	Schizophrenia: a disorder of broken brain bioenergetics.. <b>2022,</b>	0
187	Validity and Reliability of the Staden Schizophrenia Anxiety Rating Scale.. <b>2022,</b> 12,	0
186	Volatile organic compounds from exhaled breath in schizophrenia.. <b>2022,</b> 1-25	0
185	Effects of taurine in mice and zebrafish behavioral assays with translational relevance to schizophrenia.	
184	Risk factors associated with readmissions of patients with severe mental disorders under treatment with antipsychotics.. <b>2022,</b> 22, 189	0
183	A Seed-Guided Latent Dirichlet Allocation Approach to Predict the Personality of Online Users Using the PEN Model. <b>2022,</b> 15, 87	0
182	Multiobjective optimization of fluphenazine nanocomposite formulation using NSGA-II method. <b>2022,</b>	
181	Toward recovery in schizophrenia: current concepts, findings, and future research directions.. <b>2022,</b>	1
180	Sex Differences in Obesity and Cognitive Function in Chinese Elderly Patients With Chronic Schizophrenia.. <b>2022,</b> 13, 742474	1
179	A Simple and Sensitive HPLC-MS/MS Assay for the Quantitation of Blonanserin and N-Desethyl Blonanserin in Rat Plasma and Its Application to Pharmacokinetic Study.. <b>2022,</b> 2022, 5914581	
178	No influence of sex on the relationship between schizotypy factors and executive control across the schizophrenia spectrum.. <b>2022,</b> 148, 325-331	
177	Rare coding variants in ten genes confer substantial risk for schizophrenia.. <b>2022,</b>	16
176	Sex differences in the blood-brain barrier: implications for mental health.. <b>2022,</b> 100989	0
175	Differential expression of miR-148b, miR-129-2 and miR-296 in animal models of schizophrenia-Relevance to NMDA receptor hypofunction.. <b>2022,</b> 210, 109024	0
174	Differential effects of chronic adolescent glucocorticoid or methamphetamine on drug-induced locomotor hyperactivity and disruption of prepulse inhibition in adulthood in mice.. <b>2022,</b> 110552	0
173	Serious Mental Illness. <b>2022,</b> 145-168	
172	HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia.. <b>2022,</b> 110553	0
171	Behaviors and Behavioral Disorders. <b>2022,</b> 143-276	

- 170 Evidence of discontinuity between psychosis-risk and non-clinical samples in the neuroanatomical correlates of social function.. **2022**, 29, 100252
- 169 Physical comorbidity and use of healthcare services in people with schizophrenia: protocol for a systematic review.. **2021**, 11, e053324
- 168 The Variants at nd Contribute to the Susceptibility of Schizophrenia With Inhibiting mRNA Expression in Peripheral Blood Leukocytes.. **2021**, 8, 785445
- 167 The Importance of Suicide Risk Formulation in Schizophrenia.. **2021**, 12, 779684 0
- 166 Early Detection and Prevention of Schizophrenic Psychosis-A Review.. **2021**, 12, 3
- 165 Atypical Antipsychotics Mediate Dynamics of Intrinsic Brain Activity in Early-Stage Schizophrenia? A Preliminary Study.. **2021**, 18, 1205-1212 0
- 164 Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review.. **2021**, 12, 789179 3
- 163 Predicting time to relapse in patients with schizophrenia according to patients' relapse history: a historical cohort study using real-world data in Sweden.. **2021**, 21, 634 1
- 162 Animal Models of Relevance to the Schizophrenia Prodrome. **2021**, 0
- 161 Sex Differences in Neurodevelopmental Disorders: A Key Role for the Immune System.. **2022**, 1 0
- 160 Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis.. **2022**, 19, e1003960 5
- 159 Association of VEGF-A and KDR polymorphisms with the development of schizophrenia.. **2022**, 0
- 158 Identifying Diagnoses of Schizophrenia Spectrum Disorder in Large Data Sets.. **2022**, appips202100696
- 157 Image\_1.JPEG. **2019**,
- 156 Image\_2.JPEG. **2019**,
- 155 Data\_Sheet\_1.docx. **2019**,
- 154 Table\_1.docx. **2018**,
- 153 Table\_1.DOCX. **2020**,

- 152 Presentation\_1.PDF. **2017**,
- 151 Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.. **2022**, 36, 517 ○
- 150 Corrigendum: Base Rates, Blindness, and Schizophrenia. **2021**, 12, 732333 ○
- 149 Early Signs of Schizophrenia and Autonomic Nervous System Dysregulation: A Literature Review.. **2019**, 16, 86-97 1
- 148 Psychotic Disorders. **2022**, 537-555
- 147 Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.. **2022**, 23, ○
- 146 Sequencing of selected chromatin remodelling genes reveals increased burden of rare missense variants in ASD patients from the Japanese population. 1-14 ○
- 145 Brain-specific deletion of GIT1 impairs cognition and alters phosphorylation of synaptic protein networks implicated in schizophrenia susceptibility.. **2022**, ○
- 144 Altered amygdala shape trajectories and emotion recognition in youth at familial high risk of schizophrenia who develop psychosis.. **2022**, 12, 202 ○
- 143 The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations.. **2022**, 59, 45-55 ○
- 142 Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study.. **2022**, 12, 173 ○
- 141 Alternative Therapy of Psychosis: Potential Phytochemicals and Drug Targets in the Management of Schizophrenia. **2022**, 13, ○
- 140 Perceptions of causal attribution and attitudes to genetic testing among people with schizophrenia and their first-degree relatives.. **2022**, ○
- 139 Specialised minds: extending adaptive explanations of personality to the evolution of psychopathology. 1-29 ○
- 138 Tobacco Treatment Outcomes for Hospital Patients With and Without Mental Health Diagnoses. **2022**, 13, ○
- 137 Multidimensional analysis of adult patients' care trajectories before a first diagnosis of schizophrenia. **2022**, 8, ○
- 136 New Paradigms of Old Psychedelics in Schizophrenia. **2022**, 15, 640 1
- 135 Client Racial Composition in First-Episode Psychosis Programs Compared With Compositions in Program Service Areas. ○

- 134 Ultra-rare and common genetic variant analysis converge to implicate negative selection and neuronal processes in the aetiology of schizophrenia.
- 133 Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States. **2022**, 22, 0
- 132 Dual hit mouse model to examine the long-term effects of maternal immune activation and post-weaning social isolation on schizophrenia endophenotypes. **2022**, 430, 113930
- 131 Schizophrenia Spectrum and Other Psychotic Disorders. **2022**,
- 130 Exploring Brain Structural and Functional Biomarkers in Schizophrenia via Brain-Network-Constrained Multi-View SCCA. 16,
- 129 Associations Between Depression, Anxiety, and Multiple Disease Outcomes: A Phenotype x Phenome-Wide Association Study in Electronic Health Records.
- 128 Limitations of access to antipsychotics in Canada: loss of the old and unavailability of the new options.
- 127 Can incentives improve antipsychotic adherence in major mental illness? A mixed-methods systematic review. **2022**, 12, e059526 0
- 126 Impact of psychiatric disorders. **2022**,
- 125 Preserved Unconscious Processing in Schizophrenia: The Case of Motivation.
- 124 Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction. **2022**, 23, 7092 1
- 123 A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. **2022**, 36, 659-679 4
- 122 miR-146a and miR-200b alter cognition by targeting NMDA receptor subunits.
- 121 Acute medical workup for new-onset psychosis in children and adolescents: A retrospective cohort.
- 120 Doenãs cardiovasculares e uso de antipsicóticos na esquizofrenia: uma revisã. 1
- 119 The hidden link between circadian entropy and mental health disorders. **2022**, 12, 2
- 118 Machine learning for prediction of schizophrenia using genetic and demographic factors in the UK biobank. **2022**, 246, 156-164 0
- 117 Psychopharmacological treatment patterns prior to a schizophrenia diagnosis: A Danish nationwide study. **2022**, 246, 268-276

- 116 Prevalence and gender distribution of trichotillomania: A systematic review and meta-analysis. **2022**, 153, 73-81 ○
- 115 Comparison of Healthcare Utilization between Telemedicine and Standard Care: A Propensity-score Matched Cohort Study Among Individuals with Chronic Psychotic Disorders in Ontario, Canada.
- 114 Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia. Volume 16, 1805-1817 ○
- 113 Toxoplasma infection in male mice alters dopamine-sensitive behaviors and host gene expression patterns associated with neuropsychiatric disease. **2022**, 16, e0010600
- 112 Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats. ○
- 111 Perceptions of Family Caregivers of Patients with Schizophrenia Towards Antipsychotics Associated Side-Effects in China:A Qualitative Study. Volume 16, 2171-2179
- 110 Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom. **2022**, 22,
- 109 Efficacy and safety of intermittent theta-burst stimulation in patients with schizophrenia: A meta-analysis of randomized sham-controlled trials. 13, 1
- 108 Increased NLRP3 inflammasome expression in peripheral blood mononuclear cells of patients with schizophrenia: a case-control study. 1-7
- 107 CACNA1C Gene rs1006737 Polymorphism Affects Cognitive Performance in Chinese Han Schizophrenia. Volume 18, 1697-1704 ○
- 106 Predicting symptom response and engagement in a digital intervention among individuals with schizophrenia and related psychoses. 13,
- 105 Exploration of the Barriers to Clozapine Prescribing in Patients with Treatment-Resistant Schizophrenia: A Qualitative Study.
- 104 Metabolite Profiling of Clozapine in Patients Switching Versus Maintaining Treatment. Publish Ahead of Print, ○
- 103 Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. Volume 18, 1705-1713
- 102 Generation of two human induced pluripotent stem cell lines from peripheral blood mononuclear cells of clozapine-tolerant and clozapine-induced myocarditis patients with treatment-resistant schizophrenia. **2022**, 63, 102877
- 101 Landscape, barriers, and facilitators of scientific productivity in schizophrenia research in Southeast Asia: A bibliometric analysis. **2022**, 81, 104330 ○
- 100 A longitudinal investigation of GABA, glutamate, and glutamine across the insula during antipsychotic treatment of first-episode schizophrenia. **2022**, 248, 98-106 ○
- 99 Default mode network alterations underlie auditory verbal hallucinations in schizophrenia. **2022**, 155, 24-32

- 98 Reduced interpersonal neural synchronization in right inferior frontal gyrus during social interaction in participants with clinical high risk of psychosis: An fNIRS-based hyperscanning study. **2022**, 110634 1
- 97 Item-level endorsement on the Prodromal Questionnaire in a large non-clinical sample. **2022**, 248, 309-319 0
- 96 Schizophrenia classification using machine learning on resting state EEG signal. **2023**, 79, 104233 1
- 95 Biological hypotheses, risk factors, and biomarkers of schizophrenia. **2023**, 120, 110626 0
- 94 Molecular mechanisms underlying cannabis-induced risk of psychosis. **2022**, 197-242 0
- 93 Psychiatric profile in children and youth with 22q11.2 deletion syndrome. **2022**, 302-321 0
- 92 Brain targeting drug delivery systems for the management of brain disorders. **2022**, 289-345 0
- 91 Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. **2022**, 2022, 1 1
- 90 Deep proteomics identifies shared molecular pathway alterations in synapses of schizophrenia and bipolar disorder patients and mouse model. 0
- 89 Delayed improvements in visual memory task performance among chronic schizophrenia patients after high-frequency repetitive transcranial magnetic stimulation. **2022**, 12, 1169-1182 0
- 88 Physical Health Impairment and Exercise as Medicine in Severe Mental Disorders: A Narrative Review. **2022**, 8, 1 1
- 87 Behavioral features and disorganization of oscillatory activity in C57BL/6J mice after acute low dose MK-801 administration. 16, 0
- 86 Pathological oligodendrocyte precursor cells revealed in human schizophrenic brains and trigger schizophrenia-like behaviors and synaptic defects in genetic animal model. 0
- 85 Magnetic resonance imaging of the dopamine system in schizophrenia [A scoping review]. 13, 0
- 84 Autism Spectrum Disorder: a Review of Behavioral and Psychiatric Challenges Across the Lifespan. **2022**, 4, 1 1
- 83 The burden of illness for patients with schizophrenia and primary negative symptoms: A systematic literature review. **2022**, 248, 341-344 0
- 82 Mechanisms underpinning *Carpollbia lutea* G. Don ethanol extract's neurorestorative and antipsychotic-like activities in an NMDA receptor antagonist model of schizophrenia. **2022**, 115767 0
- 81 Effects of bilateral, bipolar-nonbalanced, frontal transcranial Direct Current Stimulation (tDCS) on negative symptoms and neurocognition in a sample of patients living with schizophrenia: Results of a randomized double-blind sham-controlled trial. **2022**, 155, 430-442 0

80	DNA Methylation Pattern of Gene Promoters of MB-COMT, DRD2, and NR3C1 in Turkish Patients Diagnosed with Schizophrenia. <b>2022</b> , 20, 685-693	1
79	Beta-2 adrenergic receptor agonism alters astrocyte phagocytic activity and has potential applications to psychiatric disease.	0
78	Schizophrenia: One Name, Many Different Manifestations. <b>2022</b> ,	1
77	Thematic analysis of the raters' experiences administering scales to assess depression and suicide in Arab schizophrenia patients. <b>2022</b> , 22,	0
76	Genetic and Geographical Associations With Six Dimensions of Psychotic Experiences in Adolescence.	0
75	Magnocellular and parvocellular contributions to brain network dysfunction during learning and memory: Implications for schizophrenia. <b>2022</b> ,	0
74	Psychotic relapse in people with schizophrenia within 12 months of discharge from acute inpatient care: protocol for development and validation of a prediction model based on a retrospective cohort study in three psychiatric hospitals in Japan. <b>2022</b> , 6,	0
73	Factors Influencing Self-Management of Schizophrenia: A Cross-Sectional Study. 1-8	0
72	NOWE KIERUNKI POSZUKIWAŁEKÓW ANTYPSCYCHOTYCZNYCH. <b>2014</b> , 13, 21-27	0
71	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. <b>2022</b> , 305-359	0
70	Associated genetics and connectomic circuitry in schizophrenia and bipolar disorder. <b>2022</b> ,	0
69	Polygenic risk scores for schizophrenia and major depression are associated with socio-economic indicators of adversity in two British community samples. <b>2022</b> , 12,	0
68	Reduced cortical neuron number and neuron density in schizophrenia with focus on area 24: a post-mortem case-control study.	0
67	Factors and their weight in reducing life expectancy in schizophrenia. <b>2022</b> , 250, 67-75	1
66	A Systematic Review and Meta-analysis of the Prevalence of Schizophrenia in China from 2000 to 2020 ABSTRACT Background The prevalence of schizophrenia is influenced by many factors. The rapid development of China's recent development may have an impact on the incidence rate of schizophrenia. To understand the prevalence of schizophrenia and the trend of nearly twenty years in China, providing scientific basis for early prevention and treatment by meta-analysis. Methods A systematic literature retrieval p.	0
65	Psychotic Disorders in Hispanics. <b>2022</b> , 33-47	0
64	Catalase and interleukin-6 serum elevation in a prediction of treatment-resistance in male schizophrenia patients. <b>2023</b> , 79, 103400	0
63	Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. <b>2022</b> , 2022,	0

- 62 Keeping the balance: Trade-offs between human brain evolution, autism, and schizophrenia. 13, 0
- 61 Face pareidolia in male schizophrenia. **2022**, 8, 0
- 60 Pharmacogenetics and Schizophrenia Can Genomics Improve the Treatment with Second-Generation Antipsychotics?. **2022**, 10, 3165 0
- 59 Increased blood neutrophil extracellular traps (NETs) associated with early life stress: translational findings in recent-onset schizophrenia and rodent model. **2022**, 12, 0
- 58 Effects of psychological treatments on functioning in people with Schizophrenia: a systematic review and meta-analysis of randomized controlled trials. 2
- 57 Virtual histology of morphometric similarity network after risperidone monotherapy and imaging-epigenetic biomarkers for treatment response in first-episode schizophrenia. **2022**, 103406 0
- 56 Schizophrenie. **2023**, 9-57 0
- 55 Gene expression meta-analysis in patients with schizophrenia reveals up-regulation of RGS2 and RGS16 in Brodmann Area 10. 0
- 54 Reviewing the Potential Therapeutic Approaches Targeting the Modulation of Gastrointestinal Microflora in Schizophrenia. **2022**, 23, 16129 0
- 53 Psychiatric genomics, mental health equity, and intersectionality: A framework for research and practice. 13, 0
- 52 A novel ternary pattern-based automatic psychiatric disorders classification using ECG signals. 6
- 51 Methylome-wide association study of different responses to risperidone in schizophrenia. 13, 0
- 50 CCPNet136: automated detection of schizophrenia using carbon chain pattern and iterative TQWT technique with EEG signals. 0
- 49 Placebo versus no treatment for people with schizophrenia. **2023**, 2023, 0
- 48 Impact of paternal age on assisted reproductive technology outcomes and offspring health: a systematic review 0
- 47 Short-term Medication Effects on Brain Functional Activity and Network Architecture in First-Episode psychosis: a longitudinal fMRI study. 0
- 46 Assessing the burden of rare DNA methylation deviations in schizophrenia. 0
- 45 Contributing risk factors of common psychiatric disorders in the Pakistani population. 0



- 44 Copy Number Variations and Schizophrenia. ○
- 43 The role of urokinase, T-cadherin, and adiponectin in the development of schizophrenia, bipolar disorder, and Alzheimer's disease (literature review). **2022**, 925-937 ○
- 42 Cognitive Rehabilitation in Schizophrenia-Associated Cognitive Impairment: A Review. **2023**, 15, 12-23 ○
- 41 Application of machine learning methods in predicting schizophrenia and bipolar disorders: A systematic review. **2023**, 6, ○
- 40 Metabolic Syndrome in Adults Receiving Clozapine; The Need for Pharmacist Support. **2023**, 11, 23 ○
- 39 Association between obsessive-compulsive disorder and the risk of schizophrenia using the Korean National Health Insurance Service-National Sample Cohort: a retrospective cohort study. **2023**, 32, ○
- 38 DRAGON-Data: a platform and protocol for integrating genomic and phenotypic data across large psychiatric cohorts. **2023**, 9, ○
- 37 Insights into the role of intracellular calcium signaling in the neurobiology of neurodevelopmental disorders. 17, ○
- 36 Parental perceptions of second opinion consultations for recent onset schizophrenia. ○
- 35 Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States. **2023**, 26, 525-536 ○
- 34 Effects of exercise intervention on psychotic symptoms: A meta-analysis and hypothetical model of neurobiological mechanisms. **2023**, 110771 ○
- 33 Maladaptive explore/exploit trade-offs in schizophrenia. **2023**, 46, 341-354 ○
- 32 Psychotic Disorders and Organ Transplantation. **2022**, 33-38 ○
- 31 Pharmacological screening of silibinin for antischizophrenic activity along with its acute toxicity evaluation in experimental animals. 14, ○
- 30 Dual Role of the P2X7 Receptor in Dendritic Outgrowth during Physiological and Pathological Brain Development. **2023**, 43, 1125-1142 ○
- 29 Higher stress response and altered quality of life in schizophrenia patients with low membrane levels of docosahexaenoic acid. 14, ○
- 28 The contribution of copy number variants to psychiatric symptoms and cognitive ability. ○
- 27 Structure/function interrelationships and illness insight in patients with schizophrenia: a multimodal MRI data fusion study. ○

- 26 Schizophrenia Spectrum and Other Psychotic Disorders. **2023**, 469-492 ○
- 25 Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. **2023**, 322, 115138 ○
- 24 The effect of failed community mental health centers on non-white mortality. ○
- 23 A Sex-Dependent Association Between Doxycycline Use and Development of Schizophrenia. ○
- 22 Human-specific evolutionary markers linked to foetal neurodevelopment modulate brain surface area in schizophrenia. ○
- 21 Practitioner Review: Psychosis in children and adolescents. ○
- 20 The Autism Spectrum: Behavioral, Psychiatric and Genetic Associations. **2023**, 14, 677 ○
- 19 Psychotic Disorders (Schizophrenia] **2023**, 263-282 ○
- 18 Machine learning-based predictive models and drug prediction for schizophrenia in multiple programmed cell death patterns. 16, ○
- 17 Effectiveness of Clozapine on Employment Outcomes in Treatment-Resistant Schizophrenia: A Retrospective Bidirectional Mirror-Image Study. Volume 19, 615-622 ○
- 16 The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders. **2023**, 255-285 ○
- 15 Retinal layers and symptoms and inflammation in schizophrenia. ○
- 14 Rare Variants in Pharmacogenes Influence Clozapine Metabolism in Individuals with Schizophrenia. ○
- 13 Efficacy and safety of Transcranial Direct Current Stimulation (tDCS) on Cognitive Function in Chronic Schizophrenia with Tardive Dyskinesia (TD): a randomized, double-blind, sham-controlled, clinical trial. ○
- 12 Sudden Cardiac Death in People With Schizophrenia. **2023**, ○
- 11 Relationship between function and structure in the visual cortex in healthy individuals and in patients with severe mental disorders. **2023**, 332, 111633 ○
- 10 Le potentiel thérapeutique du cannabidiol chez les sujets présentant un trouble du spectre psychotique : une revue systématique de la littérature sur les essais contrôlés randomisés. **2023**, ○
- 9 Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia. **2023**, 13, 204512532311581 ○

- 8 Interhemispheric differences of pyramidal cells in the primary motor cortices of schizophrenia patients investigated postmortem. ○
- 7 SMAD genes are up-regulated in brain and blood samples of individuals with schizophrenia. ○
- 6 Beyond the binary: Gender inclusivity in schizophrenia research. **2023**, ○
- 5 Up-Regulation of S100 Gene Family in Brain Samples of a Subgroup of Individuals with Schizophrenia: Meta-analysis. ○
- 4 The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors. ○
- 3 Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety. Volume 19, 749-757 ○
- 2 Post-incident debriefing for people with schizophrenia after coercive measures. **2023**, 2023, ○
- 1 Altered MANF and RYR2 concentrations associated with hypolipidemia in the serum of patients with schizophrenia. **2023**, 163, 142-149 ○